

# Intracrine androgen biosynthesis, metabolism and action revisited

Schiffer, Lina; Arlt, Wiebke; Storbeck, Karl-Heinz

DOI:

[10.1016/j.mce.2017.08.016](https://doi.org/10.1016/j.mce.2017.08.016)

License:

Creative Commons: Attribution (CC BY)

*Document Version*

Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*

Schiffer, L, Arlt, W & Storbeck, K-H 2018, 'Intracrine androgen biosynthesis, metabolism and action revisited', *Molecular and Cellular Endocrinology*, vol. 465, pp. 4-26. <https://doi.org/10.1016/j.mce.2017.08.016>

[Link to publication on Research at Birmingham portal](#)

## General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.



# Intracrine androgen biosynthesis, metabolism and action revisited



Lina Schiffer<sup>a</sup>, Wiebke Arlt<sup>a,\*</sup>, Karl-Heinz Störbeck<sup>a,b</sup>

<sup>a</sup> Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK

<sup>b</sup> Department of Biochemistry, Stellenbosch University, Stellenbosch 7600, South Africa

## ARTICLE INFO

### Article history:

Received 16 May 2017

Received in revised form

28 August 2017

Accepted 28 August 2017

Available online 1 September 2017

### Keywords:

Androgens

Intracrinology

Steroid biosynthesis

Hormone-dependent cancer

Testosterone

11-oxygenated androgens

## ABSTRACT

Androgens play an important role in metabolic homeostasis and reproductive health in both men and women. Androgen signalling is dependent on androgen receptor activation, mostly by testosterone and 5 $\alpha$ -dihydrotestosterone. However, the intracellular or intracrine activation of C<sub>19</sub> androgen precursors to active androgens in peripheral target tissues of androgen action is of equal importance. Intracrine androgen synthesis is often not reflected by circulating androgens but rather by androgen metabolites and conjugates. In this review we provide an overview of human C<sub>19</sub> steroid biosynthesis including the production of 11-oxygenated androgens, their transport in circulation and uptake into peripheral tissues. We conceptualise the mechanisms of intracrinology and review the intracrine pathways of activation and inactivation in selected human tissues. The contribution of liver and kidney as organs driving androgen inactivation and renal excretion are also highlighted. Finally, the importance of quantifying androgen metabolites and conjugates to assess intracrine androgen production is discussed.

© 2018 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

## Contents

1. Introduction .....	5
2. <i>De-novo</i> androgen biosynthesis in the adrenal and gonads .....	5
2.1. Adrenal androgen biosynthesis .....	5
2.2. Ovarian C <sub>19</sub> steroid biosynthesis .....	8
2.3. Testicular C <sub>19</sub> biosynthesis .....	8
3. C <sub>19</sub> steroids in circulation .....	8
4. C <sub>19</sub> steroid metabolism in peripheral target tissues – principles of intracrine androgen activation and inactivation .....	10
4.1. Cellular uptake and deconjugation .....	10
4.2. Principles of intracrine androgen steroid metabolism .....	11
4.3. Enzymes involved in intracrine androgen metabolism .....	11
5. Pathways of peripheral androgen activation .....	13
5.1. The classical androgen biosynthesis pathway .....	13
5.2. The alternate 5 $\alpha$ -dione pathway .....	14
5.3. The backdoor pathway .....	14

**Abbreviations:** 11KA4, 11-keto-androstenedione; 11KDHT, 11-keto-5 $\alpha$ -dihydrotestosterone; 11KT, 11-keto-testosterone; 11OHA4, 11 $\beta$ -hydroxy-androstenedione; 11OHDHT, 11 $\beta$ -hydroxy-5 $\alpha$ -dihydrotestosterone; 11OHT, 11 $\beta$ -hydroxy-testosterone; 17 $\alpha$ HP, 5 $\alpha$ -pregnane-17 $\alpha$ -ol-3,20-one; 17OHPROG, 17 $\alpha$ -hydroxy-progesterone; 3 $\alpha$ -adiol, 5 $\alpha$ -androstane-3 $\alpha$ ,17 $\beta$ -diol; 5 $\alpha$ -dione, 5 $\alpha$ -androstane-3,17-dione; 5 $\alpha$ -diol, androst-5-ene-3 $\beta$ ,17 $\beta$ -diol; A4, androstenedione (androst-4-ene-3,17-dione); AKR, aldo-keto reductase; AR, androgen receptor; AST, androsterone (5 $\alpha$ -androstane-3 $\alpha$ -ol-17-one); CHOL, cholesterol; CRPC, castration resistant prostate cancer; CYP, cytochrome P450; DHEA, dehydroepiandrosterone (androst-5-ene-3 $\beta$ -ol-17-one); DHEAS, dehydroepiandrosterone sulfate; EpiAST, 5 $\alpha$ -androstane-3 $\beta$ -ol-17-one; EpiT, epitestosterone (17 $\alpha$ -hydroxy-testosterone, androst-4-ene-17 $\alpha$ -ol-3-one); E1, estrone; E1S, estrone sulfate; E2, estradiol; ETIO, etiochonanalone (5 $\beta$ -androstane-3 $\alpha$ -ol-17-one); DHT, 5 $\alpha$ -dihydrotestosterone (5 $\alpha$ -androstane-17 $\beta$ -ol-3-one); HSD, hydroxysteroid dehydrogenase; OATP, organic anion-transporting polypeptide; PAPS, 3'-phospho-adenosine-5'-phosphosulfate; PCOS, polycystic ovary syndrome; Pdiol, 5 $\alpha$ -pregnane-3 $\alpha$ ,17 $\alpha$ -diol-20-one; PORD, cytochrome P450 oxidoreductase deficiency; PREG, pregnenolone; PROG, progesterone; StAR, steroidogenic acute regulatory protein; SHBG, sex hormone-binding globulin; STS, steroid sulfatase; SULT, sulfotransferase; T, testosterone (androst-4-ene-17 $\beta$ -ol-3-one); UGT, uridine diphosphate-glucuronosyl transferase.

\* Corresponding author.

E-mail address: [w.arlt@bham.ac.uk](mailto:w.arlt@bham.ac.uk) (W. Arlt).

<http://dx.doi.org/10.1016/j.mce.2017.08.016>

0303-7207/© 2018 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

5.4. The 11-oxygenated androgen pathways .....	14
6. Directionality of biosynthetic steps, phase 1 metabolism and conjugation .....	14
7. Intracrinology in metabolic target tissues .....	14
7.1. Adipose tissue .....	14
7.2. Skeletal muscle .....	15
7.3. Liver .....	15
7.3.1. Hepatic phase 1 metabolism .....	15
7.3.2. Hepatic phase 2 metabolism .....	16
7.3.3. The liver as a target tissue of androgen action .....	16
8. Intracrine androgen metabolism in reproductive target tissues .....	16
8.1. Breast and endometrium .....	16
8.2. Prostate .....	17
8.3. Placenta .....	17
9. Intracrine androgen metabolism in other tissues .....	18
9.1. Skin .....	18
9.2. Salivary gland .....	18
10. Kidney androgen metabolism and renal excretion of androgens .....	18
10.1. The kidney as an androgen-metabolising organ .....	18
10.2. Renal excretion and analytical considerations .....	19
11. Conclusions .....	19
Acknowledgments .....	20
References .....	20

## 1. Introduction

Androgens (from the greek “*andro*” meaning male or man) are traditionally considered male sex steroids responsible for the maintenance of male characteristics via the activation of the Androgen Receptor (AR), a ligand-induced nuclear receptor that functions as transcription factor after activation. The primary androgen found in men is testosterone (T, androst-4-ene-17 $\beta$ -ol-3-one), which is produced by the Leydig cells of the testes, and released into circulation. The androgen signal can be further amplified in selected target tissues where T is reduced to 5 $\alpha$ -dihydrotestosterone (DHT, 5 $\alpha$ -androst-17 $\beta$ -ol-3-one), which is considered the most potent natural androgen (Pretorius et al., 2016; Rege et al., 2013; Storbeck et al., 2013; Wilson and French, 1976). While the adrenal glands only produce low levels of the active androgen T, they produce significant levels of the inactive C<sub>19</sub> androgen precursors dehydroepiandrosterone (DHEA, androst-5-ene-3 $\beta$ -ol-17-one) and its sulfate ester DHEAS, androstenedione (A4, androst-4-ene-3,17-dione) and 11 $\beta$ -hydroxyandrostenedione (11OHA4), which in the majority are released into circulation (Rege et al., 2013). After uptake into a peripheral tissue with the required enzyme machinery, these androgen precursors are converted into active androgens which elicit a physiological response. This distinct mechanism of androgen precursor activation, action and inactivation in peripheral androgen-target cells was first termed intracrinology by Labrie et al. (1988) and is linked to classical genomic androgen signalling in both men and women. The importance of intracrinology has been well documented by several authors during the last 25 years after the initial description by Labrie (1991, 2015), Labrie et al. (2001, 2017) and significant progress has been made in understanding the tissue-specificity of intracrinology and its dysregulation, which is associated with, for example, metabolic dysfunction and hormone dependent cancers. In this review, we give an overview of the journey of C<sub>19</sub> steroids from their synthesis to their secretion as summarised in Fig. 1. We provide an overview of human C<sub>19</sub> steroid biosynthesis, the transport of these steroids in circulation and uptake into peripheral target tissues of androgen action. We conceptualise the mechanisms of intracrinology and review the intracrine pathways and effects in selected tissues. The contribution of liver and kidney as organs driving androgen


inactivation and excretion are also highlighted. For ease of reference the enzymes discussed in this review are summarised in Table 1 along with the names of the corresponding genes and their enzymatic activities.

## 2. De-novo androgen biosynthesis in the adrenal and gonads

### 2.1. Adrenal androgen biosynthesis

Adrenal androgen biosynthesis takes place in the *zona reticularis* and proceeds via the classical  $\Delta^5$  pathway (Miller and Auchus, 2011; Turcu and Auchus, 2015) as depicted in Fig. 2. The specific co-localisation of the cytochrome P450 17 $\alpha$ -hydroxylase/17,20-lyase (CYP17A1) and cytochrome *b*<sub>5</sub> in the *zona reticularis* favours the 17,20-lyase activity of CYP17A1 and thus C<sub>19</sub> steroid production. Furthermore, the expression of HSD3B2 encoding 3 $\beta$ -hydroxysteroid dehydrogenase/ $\Delta^5$ -isomerase type 2 (HSD3B2) is relatively low in the *zona reticularis*, thereby ensuring the activity of the  $\Delta^5$  pathway and the production of DHEA.

DHEA is converted to DHEAS by DHEA sulfotransferase (sulfotransferase 2A1, SULT2A1) and as such DHEAS is the major C<sub>19</sub> steroid secreted by the adrenal, circulating in low micromolar concentrations. Importantly, all sulfotransferases (SULTs) require 3'-phospho-adenosine-5'-phosphosulfate (PAPS), the ubiquitous sulfate donor, which in humans is produced by the two isoforms of PAPS synthase from sulfate and ATP. Mutations of PAPS synthase type 2 (PAPSS2) lead to impaired PAPS synthesis and thus impaired sulfation, which results in enhanced conversion of DHEA to active androgens. Clinically this results in androgen excess manifesting with premature pubarche and a phenotype in women resembling polycystic ovary syndrome (PCOS), also observed in heterozygous carriers of major loss-of-function mutations (Noordam et al., 2009; Oostdijk et al., 2015). In the adrenal, DHEA can further be converted to A4 by HSD3B2 and A4 can be transformed to T by the low adrenal levels of aldo-keto-reductase family 1C3 (AKR1C3, also known as 17 $\beta$ -hydroxysteroid dehydrogenase type 5, HSD17B5), which has 17 $\beta$ -hydroxysteroid dehydrogenase (17 $\beta$ HSD) activity (Nakamura et al., 2009b; Rainey and Nakamura, 2008; Rege et al., 2013). AKR1C3 can also catalyse the conversion of some DHEA to 5-diol (androst-5-ene-3 $\beta$ ,17 $\beta$ -diol), which can be sulfated by SULT2A1 or



**Fig. 1. Schematic overview of C<sub>19</sub> steroid biosynthesis, intracrine action, metabolism and urinary excretion.** Yellow balls represent the androgen sulfate, blue balls the glucuronide. After metabolic activation the androgen binds the androgen receptor (red) and the complex translocates into the nucleus (grey) to work as transcription factor. It should be noted that while intracrine pathways play the major role for peripheral androgen action, active androgens such as T are produced by the testes and the adrenal, albeit only low levels, and these do not require activation in target tissue. CYP, cytochrome P450; HSD, hydroxysteroid dehydrogenase; SHBG, sex hormone binding globulin; STS, steroid sulfatase; SULT, sulfotransferase.


converted to T by HSD3B2. A small fraction of DHEA and 5-diol can also be esterified with fatty acids at the 3β- or 17β-hydroxyl position (Belanger et al., 1990; Hochberg, 1998). Due to the ample levels of cytochrome P450 steroid 11β-hydroxylase (CYP11B1), the adrenal gives rise to 11-oxygenated C<sub>19</sub> steroids by converting A4 and T to their 11β-hydroxyl derivatives, with 11OHA4 being the major product due to the high abundance of A4. Both 11OHA4 and 11β-

hydroxytestosterone (11OHT) may be converted to their 11-keto counterparts by the low levels of 11β-hydroxysteroid dehydrogenase type 2 (HSD11B2) present in the adrenal, though peripheral HSD11B2 may make a more significant contribution (Pretorius et al., 2017; Turcu et al., 2016). Adrenal vein sampling of healthy women has shown that the adrenal secretes DHEAS (low micromolar range) » DHEA, 11OHA4, A4 (medium nanomolar ranges) > 5-

**Table 1**

**Summary of enzymes involved in androgen biosynthesis and metabolism.** Genes are named according to HUGO nomenclature (Povey et al., 2001; Shows et al., 1979) (<http://www.genenames.org/>). In the case of multi-functional enzymes only the major activity towards C<sub>19</sub> steroids are listed. It should be noted that while hydroxysteroid dehydrogenase enzymes are, in principle, bi-directional enzymes, their directionality *in vivo* (reductive or oxidative) is regulated in part by cellular redox status.

Gene name	Enzyme name and abbreviation	Enzymatic activity towards C <sub>19</sub> steroids
AKR1C1	aldo-keto reductase 1C1, AKR1C1	reductive 3 $\alpha$ HSD (minor)
AKR1C2	aldo-keto reductase 1C2, AKR1C2	reductive 3 $\alpha$ HSD
AKR1C3	aldo-keto reductase 1C3, AKR1C3 (also known as 17 $\beta$ -hydroxysteroid dehydrogenase type 5, HSD17B5)	reductive 17 $\beta$ HSD
AKR1C4	aldo-keto reductase 1C4, AKR1C4	reductive 3 $\alpha$ HSD
AKR1D1	aldo-keto-reductase 1D1, 5 $\beta$ -reductase, AKR1D1	5 $\beta$ -reductase
CYP11A1	cytochrome P450 cholesterol side-chain cleavage, CYP11A1	C <sub>20</sub> -C <sub>22</sub> bond cleavage
CYP11B1	cytochrome P450 11 $\beta$ -hydroxylase, CYP11B1	11 $\beta$ -hydroxylase
CYP17A1	cytochrome P450 17 $\alpha$ -hydroxylase/17,20-lyase, CYP17A1	17 $\alpha$ -hydroxylation and C <sub>17</sub> -C <sub>20</sub> bond cleavage
CYP19A1	cytochrome P450 aromatase, CYP19A1	C <sub>10</sub> -C <sub>19</sub> demethylation/A-ring aromatisation
HSD3B1	3 $\beta$ -hydroxysteroid dehydrogenase type 1, HSD3B1	oxidative 3 $\beta$ HSD/ $\Delta^{5-4}$ -isomerase
HSD3B2	3 $\beta$ -hydroxysteroid dehydrogenase type 2, HSD3B2	oxidative 3 $\beta$ HSD/ $\Delta^{5-4}$ -isomerase
HSD11B1	11 $\beta$ -hydroxysteroid dehydrogenase type 1, HSD11B1	(predominantly) reductive 11 $\beta$ HSD
HSD11B2	11 $\beta$ -hydroxysteroid dehydrogenase type 2, HSD11B2	oxidative 11 $\beta$ HSD
HSD17B3	17 $\beta$ -hydroxysteroid dehydrogenase type 3, HSD17B3	reductive 17 $\beta$ HSD
HSD17B6	17 $\beta$ -hydroxysteroid dehydrogenase type 6, HSD17B6 (also known as retinol dehydrogenase, RoDH with RoDH used for the gene)	oxidative 3 $\alpha$ -HSD
PAPSS2	3'-phosphoadenosine 5'-phosphosulfate synthase 2, PAPSS2	3'-phosphoadenosine 5'-phosphosulfate synthase
SRD5A1	steroid 5 $\alpha$ -reductase type 1, SRD5A1	5 $\alpha$ -reductase
SRD5A2	steroid 5 $\alpha$ -reductase type 2, SRD5A2	5 $\alpha$ -reductase
SRD5A3	steroid 5 $\alpha$ -reductase type 3, SRD5A3	5 $\alpha$ -reductase (minor)
STS	steroid sulfatase, STS	hydrolysis of steroid sulfates
SULT2A1	sulfotransferase 2A1, also DHEA sulfotransferase, SULT2A1	sulfotransferase
SULT2B1	sulfotransferase 2B1 isoforms a and b, SULT2B1a and SULT2B1b	sulfotransferase



**Fig. 2. Schematic overview of C<sub>19</sub> steroid biosynthesis in the adrenal.** *De-novo* androgen biosynthesis in the *zona reticularis* of the adrenal proceeds via the classical  $\Delta^5$  pathway. CYP11B1 activity leads to the formation of 11-oxygenated C<sub>19</sub> steroids. Major pathways are indicated by bold arrows and arrows are labelled with the major isoform of the enzyme responsible for the reaction. Active androgens are shown in black boxes.

diol, 11-ketoandrostenedione (11KA4), T, 11OHT, 11-ketotestosterone (11KT) and DHT (low nanomolar ranges) (Rege et al., 2013). The adrenal thus secretes only very low amounts of active androgens, but mainly androgen precursors that are activated in peripheral tissues.

It should be noted that adrenal C<sub>19</sub> steroid production is initiated during adrenarche, a pre-pubertal event (approximately age 8 in girls and 9 in boys (Idkowiak et al., 2011)) unique to humans and higher primates (Abbott and Bird, 2009; Arlt et al., 2002; Auchus

and Rainey, 2004; Miller, 2008). Adrenarche is due to the development of the *zona reticularis* which is characterised by an increase in the expression of *CYP5A* (encoding cytochrome *b*<sub>5</sub>) and *SULT2A1*, and a decrease in the expression of *HSD3B2*, which in combination favours the biosynthesis of DHEA and DHEAS (Bird, 2012; Gell et al., 1996; Nakamura et al., 2009a). It is only after adrenarche that high levels of C<sub>19</sub> androgen precursors are available for peripheral activation and adrenarche thus represents the onset of significant intracrine androgen signalling in human life.



A peak of adrenal C<sub>19</sub> steroid production is reached in the third and fourth decade of human life in both men and women after which levels decline significantly (Labrie et al., 1997b). Nonetheless, 80% of the circulating DHEA in postmenopausal women is of adrenal origin with the remainder produced by the ovary (Labrie et al., 2011).

Importantly, the expression of CYP17A1 in adrenal of adult mice and rat, which are frequently used as pre-clinical models for endocrine and pharmacology studies, is minimal (Le Goascogne et al., 1991; Mostaghel et al., 2017; Rodriguez et al., 1997). Therefore, unlike humans, mouse and rat adrenals do not produce significant levels of androgen precursors (van Weerden et al., 1992) which can serve as substrates for intracrine action and are therefore not valid models for studies of human androgen intracrinology. Furthermore, while other rodents such as hamster (Cloutier et al., 1995) and guinea pig (Le Goascogne et al., 1991; Tremblay et al., 1995) do produce adrenal C<sub>19</sub> steroids due to adrenal CYP17A1 expression, CYP17A1 substrate specificity in these species is significantly different from that of the human enzyme (Cloutier et al., 1997; Tremblay et al., 1995), thus limiting comparisons to human adrenal steroidogenesis. Care should therefore be taken when choosing clinical models for studies of C<sub>19</sub> intracrine action.

## 2.2. Ovarian C<sub>19</sub> steroid biosynthesis

Ovarian steroid biosynthesis can be described by the “two-cell, two-gonadotrophin” model: Two different cell types - granulosa cells of the follicle and the surrounding theca cells - perform distinct reactions due to specific enzyme expression (Fig. 3). In addition, each cell type is differentially regulated by two pituitary hormones – follicle stimulating hormone acting on granulosa cells and luteinising hormone regulating both theca and granulosa cells (Hillier et al., 1994). Granulosa cells do not express CYP17A1 and their *de-novo* steroidogenic activity therefore stops at the stage of the C<sub>21</sub> steroids progesterone (PROG) and pregnenolone (PREG) (Voutilainen et al., 1986). These precursors diffuse into the adjacent theca cells, which express CYP17A1 and HSD3B2 (but express only low levels of CYP11A1), and serve as substrates for the production of A4 (Patel et al., 2010). A4 can either be secreted or converted to T by AKR1C3 in the theca cells (Nelson et al., 2001), but the majority of A4 diffuses back to the granulosa cells where it is converted to estrone (E1), estradiol (E2) and E1-sulfate (E1S) (Miller and Auchus, 2011). 17 $\beta$ -hydroxysteroid dehydrogenase type 1, HSD17B1, is limited to the granulosa cells, where it activates E1 to E2 (Nelson et al., 2001). While the ovary is capable of *de-novo* steroidogenesis, studies have shown that it also efficiently makes use of DHEA of adrenal origin for the production of androgens and oestrogens (Arlt et al., 1999a; Haning et al., 1985; Lebbe et al., 2017). The presence of steroid 5 $\alpha$ -reductase type 1 (SRD5A1), aldo-keto reductase 1C2 (AKR1C2), aldo-keto reductase 1C4 (AKR1C4) and 17 $\beta$ -hydroxysteroid dehydrogenase type 6 (HSD17B6) has also been demonstrated for ovarian theca cells and some of those are required for the functioning of the backdoor pathway, which produces DHT by-passing DHEA, A4 and T, (section 5.3), (Marti et al., 2017). Ovarian steroidogenesis commences with puberty when the onset of hypothalamic-pituitary-gonadal signalling leads to an increase in follicle stimulating hormone and luteinizing hormone which in turn regulate steroidogenic activity (Herbison, 2016). While ovarian steroidogenesis demonstrates a menstrual cycle-dependent profile in premenopausal women (Barbieri, 2014), the absence of ovarian follicles in the postmenopausal ovary significantly reduces the production of oestrogens (Labrie et al., 2011). The contribution of postmenopausal ovaries to circulating levels of active androgens is, however, controversial (Couzinnet et al., 2001; Fogle et al., 2007).

## 2.3. Testicular C<sub>19</sub> biosynthesis


Testicular androgen biosynthesis is carried out in the Leydig cells and, similar to the adrenal, follows the classical  $\Delta^5$  pathway with only minor contribution of the  $\Delta^4$  pathway (Fluck et al., 2003; Sherbet et al., 2003). Due to high abundance of HSD3B2 and 17 $\beta$ -hydroxysteroid dehydrogenase type 3 (HSD17B3) and the absence of SULTs, the final products are the 3-keto- $\Delta^4$  androgens A4 and T (Fig. 4). HSD17B3 function is essential for testicular T generation from A4 and it is the only human HSD17B isoform with an established deficiency syndrome. HSD17B3 deficiency results in disordered sex development in genetically male children (Boehmer et al., 1999; Mendonca et al., 1999). However, the testes also express AKR1C3 and in cases of HSD17B3 deficiency the testes still produce low amounts of T via this enzyme (Werner et al., 2012). Concentrations of androgen in testicular venous blood of healthy individuals are T (high nanomolar-low micromolar) » A4, DHEA (medium nanomolar) (Hammond et al., 1977; Ishida et al., 1990; Weinstein et al., 1974).

Unlike the fetal ovaries, the fetal testes have steroidogenic activity which peaks between 11 and 17 weeks of gestation. Fetal testicular T is essential for the development of the male internal genitalia, while the local conversion of testicular T to DHT is essential for the development of external genitalia taking place between 8 and 12 weeks of gestation (Krone et al., 2007; Sobel et al., 2004). Post-natal testicular steroidogenesis is initiated by the onset of hypothalamic-pituitary-gonadal signalling during puberty. A decline of androgens in men starting in the third decade of life can be observed as aging results in a gradual development of testicular failure due to a decreased number of Leydig cells and response to hypothalamic-pituitary signalling (Beattie et al., 2015; Golan et al., 2015). This results in a decline of circulating T concentrations of approximately 0.1 nmol/L per year (Camacho et al., 2013).


## 3. C<sub>19</sub> steroids in circulation

After production by the adrenal and gonads C<sub>19</sub> steroids are released into circulation. The concentration of these steroids that peripheral tissue is exposed to is determined by (1) the total concentration of the respective C<sub>19</sub> steroids in circulation, (2) whether or not the specific steroid is bound to sex hormone binding globulin (SHBG) or albumin and (3) the availability of mechanisms for cellular influx and efflux, although this is only relevant for conjugated steroids which require active transport across the cell membrane (Giorgi and Stein, 1981).

In Table 2, we have summarized the serum concentrations of C<sub>19</sub> steroids including androgen precursors, active androgens and their metabolites, as determined by liquid chromatography-tandem mass spectrometry in recent studies. In addition to the classical C<sub>19</sub> steroids (DHEAS, DHEA, T and A4), recent advances in mass spectrometry-based analytical methodology have allowed for the identification and quantification of non-classical androgen metabolites (Bloem et al., 2015). For example, we recently profiled classical and 11-oxygenated androgens in serum of healthy premenopausal women and premenopausal women with PCOS. We found that the 11-oxygenated androgens were the predominant C<sub>19</sub> steroids in women with PCOS (O'Reilly et al., 2016). Similar results were recently observed by another study which quantified androgen levels in patients with 21-hydroxylase deficiency (Jones et al., 2016; Turcu et al., 2016, 2017). Significantly, our study in healthy and PCOS women showed for the first time that the circulating levels of the active androgen 11KT were 3–4fold higher than that of T in healthy premenopausal women (O'Reilly et al., 2016), highlighting the important contribution of the 11-



**Fig. 3. Schematic overview of sex steroid biosynthesis in the ovaries.** Steps of ovarian *de-novo* sex steroid biosynthesis are partitioned between granulosa and theca cells, which express differential sets of steroidogenic enzymes. Black box: active androgen; grey box: active oestrogen. Besides sex steroids, the ovaries produce high levels of PROG in the corpus luteum after ovulation. Major pathways are indicated by bold arrows and all arrows are labelled with the major isoform of the enzyme responsible for the reaction.



**Fig. 4. Schematic overview of C<sub>19</sub> steroid biosynthesis in the testes.** The testes produce C<sub>19</sub> steroids via the classical Δ<sup>5</sup> pathway in the Leydig cells. Due to abundant HSD3B2 and HSD17B3, and the lack of aromatase, T is the major product making the testes the only steroidogenic organ secreting significant amounts of an active androgen (black box). Major pathways are indicated by bold arrows and arrows are labelled with the major isoform of the enzyme responsible for the reaction.

oxygenated androgens to the circulating androgen pool in women.

In both men and women, ageing leads to decreases in C<sub>19</sub> steroid production (Damgaard-Olesen et al., 2016; Haring et al., 2012; Trabert et al., 2016). However, for women it is unclear if this results from age-related decline of adrenal steroidogenesis or menopause-induced functional alterations of the ovaries or from a combination of both (Labrie et al., 2011; McConnell et al., 1998). In men, the decline can be explained by simultaneous age-related reductions of both adrenal and testicular androgen biosynthesis (Beattie et al., 2015; Camacho et al., 2013; Golan et al., 2015; Labrie et al., 1997b). Although one could easily presume that most C<sub>19</sub> steroids in circulation are produced by steroidogenic tissues, androgen metabolites released from peripheral tissue make a significant contribution to the circulating pool of C<sub>19</sub> steroids and thus highlight the importance of local androgen activation and metabolism by intracrine mechanisms. The major fractions of androgen metabolites are conjugated to facilitate their excretion. Indeed, a recent study quantifying androgen metabolites and their sulfo- and glucosconjugates in serum, showed that T and DHT circulate predominantly in their unconjugated form, while their metabolites androsterone (AST, 5 $\alpha$ -androst-3 $\alpha$ -ol-17-one), epiandrosterone

(5 $\alpha$ -androst-3 $\beta$ -ol-17-one, EpiAST) and 3 $\alpha$ -adiol (5 $\alpha$ -androst-3 $\alpha$ ,17 $\beta$ -diol) were mostly conjugated, each with specific preferences for sulfation or glucuronidation (Zang et al., 2017). It has previously been suggested that the sum of the circulating metabolites AST-glucuronide and 3 $\alpha$ / $\beta$ -adiol-glucuronide should be used as estimates of active androgens produced in peripheral tissue (Labrie et al., 1997b, 2003) (3 $\beta$ -adiol, 5 $\alpha$ -androst-3 $\beta$ ,17 $\beta$ -diol). Importantly, men and women show comparable concentrations of circulating androgen metabolites (Table 2). Quantification of increased panels of C<sub>19</sub> steroids including conjugated metabolites are needed to provide further insight into the intracrine metabolism and the role thereof in endocrine disorders.

It should be noted that all C<sub>19</sub> steroid concentrations discussed above and indicated in Table 2 refer to the total concentrations of androgens in circulation and that this is not necessarily indicative of the steroid concentration available for cellular uptake. The majority of unconjugated C<sub>19</sub> steroids circulate bound to the plasma proteins albumin or SHBG and only a small fraction (1–2%) circulates in the free form which is accessible to the target tissue. These sex steroid-binding plasma proteins therefore play a crucial role in the regulation of androgen action (Laurent et al., 2016). Although

**Table 2**  
**Serum concentrations of C<sub>19</sub> steroids determined by liquid chromatography tandem mass spectrometry.** All concentrations are shown in nmol/L except for DHEA sulfate (DHEAS), which are shown in the micromolar range. The details of the original studies are given in the footnotes below the table.

Androgen precursors	Women	Men	Androgen metabolites	Women	Men
DHEA	4.2–11.8 <sup>a</sup> 6.3–35.4 <sup>c</sup> 3.4 ± 0.03 <sup>d</sup>	6.9–30 <sup>c</sup> 15.8 <sup>g</sup> 4.1 ± 0.1 <sup>d</sup> 10–20 <sup>j</sup>	Androsterone (AST)	0.4–2.1 <sup>c</sup> 0.5 ± 0.03 <sup>d</sup> nd <sup>d</sup>	0.9–1.9 <sup>c</sup> 0.7 ± 0.03 <sup>d</sup> 19 ± 1.6 <sup>d</sup> 1250–2500 <sup>j</sup>
DHEA sulfate	3400–9600 <sup>a</sup> 701–8965 <sup>c</sup> 3337 ± 16 <sup>d</sup>	1312–14125 <sup>c</sup> 5709 <sup>g</sup> 3247 ± 50 <sup>d</sup> 4300–5400 <sup>j</sup>	AST-glucuronide	28–467 <sup>c</sup> 89 ± 0.7 <sup>d</sup> 2.1–170 <sup>e</sup> 0.6 ± 0.03 <sup>d</sup>	59–248 <sup>c</sup> 104 ± 1.4 <sup>d</sup> 86–150 <sup>h</sup> 0.3 ± 0.02 <sup>d</sup>
A4	3.3–9.2 <sup>a</sup> 1.2–2.82 <sup>b</sup> 1.1–8.7 <sup>c</sup>	2.3–5.5 <sup>c</sup> 3.64 <sup>g</sup>	EpiAST EpiAST-sulfate	123±3 <sup>d</sup>	105 ± 3.2 <sup>d</sup> 500–850 <sup>j</sup>
5-androstenediol (5-diol)	1.5 ± 0.07 <sup>d</sup>	1.7 ± 0.2 <sup>d</sup>	EpiAST-glucuronide 3α-androstenediol (3α-adiol)	78 ± 0.4 <sup>d</sup> nq <sup>d</sup>	76 ± 1.3 <sup>d</sup> 0.2 ± 0.02 <sup>d</sup>
5-diol-sulfate	215 ± 21 <sup>d</sup>	178 ± 10 <sup>d</sup> 250–500 <sup>j</sup>	3α-adiol-sulfate 3α-adiol-3-glucuronide	nd <sup>d</sup> 0.6–8.4 <sup>c</sup> 0.5–9.2 <sup>e</sup>	nd <sup>d</sup> 1.3–6.7 <sup>c</sup> 2.0–3.8 <sup>h</sup>
5α-androstanedione	0.5–2.6 <sup>c</sup>	1.0–1.5 <sup>c</sup>	3α-adiol-17-glucuronide	0.3–10 <sup>c</sup> 0.5–12 <sup>e</sup>	6.2–8.8 <sup>c</sup> 5.4–11 <sup>h</sup>
11OHA4	4.9–12.5 <sup>a</sup>	2.3–5.1 <sup>i</sup>	DHEA-glucuronide	0.9 ± 0.001 <sup>d</sup>	0.7 ± 0.03 <sup>d</sup>
11KA4	2–3.9 <sup>a</sup>	0.7–1.4 <sup>i</sup>	7αOH-DHEA	0.08–1.4 <sup>f</sup>	
11OHT	0.1–0.3 <sup>a</sup>	0.3–0.7 <sup>i</sup>	7βOH-DHEA	0.08–0.9 <sup>f</sup>	
<b>Active Androgens</b>			7-oxo-DHEA	0.03–0.6 <sup>f</sup>	
T	0.2–0.5 <sup>a</sup> 0.58–1.1 <sup>b</sup> 0.4–4.1 <sup>c</sup> 1.1 ± 0.09 <sup>d</sup>	7.4–14 <sup>c</sup> 16.85 <sup>g</sup> 15.6 ± 0.6 <sup>d</sup> 10–20 <sup>j</sup>	16OH-DHEA-sulfate T-sulfate T-glucuronide	nd <sup>d</sup> nd <sup>d</sup> 0.8 ± 0.02 <sup>d</sup>	100–200 <sup>j</sup> nd <sup>d</sup> 26.5 ± 0.1 <sup>d</sup>
Calculated free T	0.0056–0.0122 <sup>b</sup>	0.3780 <sup>g</sup>	DHT-sulfate	0.3–2.7 <sup>c</sup>	2.5–3.5 <sup>c</sup>
DHT	0.2–0.9 <sup>c</sup> 0.4–0.01 <sup>d</sup>	0.9–2 <sup>c</sup> 1.2 ± 0.09 <sup>d</sup>	DHT-glucuronide	nd <sup>d</sup>	nd <sup>d</sup>
11KT	1.2–1.8 <sup>a</sup>	1.0–2.6 <sup>i</sup>	5-diol-glucuronide	nd <sup>d</sup> nq <sup>d</sup>	nd <sup>d</sup> nq <sup>d</sup>

<sup>a</sup> O'Reilly et al. (2016), interquartile range, n = 49, age interquartile range 23–32.  
<sup>b</sup> Haring et al. (2012), interquartile range, n = 985, age 20–80.  
<sup>c</sup> Trabert et al. (2016), min-max, pre- and postmenopausal women, n = 15.  
<sup>d</sup> Zang et al. (2017), mean ± standard deviation for triplicate of pooled commercial serum.  
<sup>e</sup> Labrie et al. (2006), min-max, pre- and postmenopausal women, n = 424.  
<sup>f</sup> Ke et al. (2016), min-max, pre- and postmenopausal women, n = 34.  
<sup>g</sup> Damgaard-Olesen et al. (2016), geometric mean, n = 72, age 30–<40.  
<sup>h</sup> Vandenput et al. (2007), interquartile range, n = 1086, age interquartile range 18.4–19.3.  
<sup>i</sup> Turcu et al. (2016), interquartile range, combined values for 19 men and 19 women, age 3–59.  
<sup>j</sup> Sanchez-Guijo et al. (2016), interquartile range estimated from Fig. 2, n = 60, age range 18–60.

albumin binds all unconjugated steroids with low affinities (μmolar ranges), it makes a significant contribution to steroid binding due to its high abundance (Dunn et al., 1981). In contrast, SHBG binds sex steroids (including active androgens, oestrogens, precursors and metabolites (Avvakumov et al., 2010; Cherkasov et al., 2008; Dunn et al., 1981; Grishkovskaya et al., 2002)) with high specificity and affinity (nanomolar ranges) (reviewed in (Hammond, 2016)). Abnormal levels of SHBG and mutations altering the affinity for its ligands are associated with androgen excess and a PCOS phenotype, but have also been implicated in the pathogenesis of cancer and metabolic dysfunction (Hammond, 2016; Hogeveen et al., 2002).

It is therefore preferable to consider the bioactive fraction in addition to total concentrations when considering the bioactivity of circulating androgens. Several indirect (mathematical) and direct (experimental) approaches can be used (Vermeulen et al., 1999). The “free fraction” (non protein-bound fraction) and the “bioavailable fraction” (unbound and albumin-bound fractions) can be estimated by calculations using total androgen, albumin and SHBG concentrations. The “free androgen index” is defined as (total T\*100)/SHBG. Alternatively, free T concentrations can be measured by equilibrium dialysis and the non SHBG-bound fraction can be determined by differential ammonium sulfate precipitation. Free T concentrations usually range around 1–2% of total T and are also age-dependent in women (Haring et al., 2012) and men (Camacho et al., 2013; Damgaard-Olesen et al., 2016). To date, the binding of 11-oxygenated androgens to SHBG and albumin has not been

investigated. The fraction of free 11KT relative to that of T is therefore unknown and needs to be determined to gain further insight into the potential physiological role of this potent androgen.

Interestingly, DHEA and 5-diol can be acylated with fatty acids by plasma lecithin:cholesterol acyltransferase located on high density lipoproteins (Jones and James, 1985; Lavallee et al., 1996). The C<sub>19</sub> steroid fatty acid ester can then be transferred to other lipoproteins. DHEA-fatty acid esters can be taken up by peripheral cells via lipoprotein receptors (Lavallee et al., 1996; Roy and Belanger, 1989). Circulating DHEA-fatty acids have been shown to account for ~9% of total DHEA in serum (Wang et al., 2011).

#### 4. C<sub>19</sub> steroid metabolism in peripheral target tissues – principles of intracrine androgen activation and inactivation

##### 4.1. Cellular uptake and deconjugation

Circulating, bioavailable androgens and their precursors must cross the plasma membrane of target cells to be (1) metabolised by enzymes that are located intracellularly in the cytosol or membrane of the endoplasmic reticulum and/or (2) to activate the AR, which is localised in the cytosol prior to activation by a suitable ligand. While unconjugated steroids can freely diffuse across the membrane due to their hydrophobic nature, steroid conjugates (sulfates and glucuronides) are hydrophilic and require active transport mechanisms by transmembrane proteins (Giorgi and Stein, 1981).



Additionally, de-conjugation is required after influx before the steroid can be metabolised and/or interact with its receptor. Organic anion-transporting polypeptides (OATPs) belong to the solute carrier organic anion (SLCO) transporter gene superfamily and are the primary transporters for the influx of conjugated steroids, while multi drug resistant (MDR) proteins belonging to the ATP-binding cassette (ABC) transporters are the primary transporters for the efflux of conjugated steroids (Deeley et al., 2006; Mueller et al., 2015). The access of a conjugated steroid to a specific cell is determined by (1) the expression level of transporters in combination with (2) the substrate specificity and (3) the transport kinetics of the respective transporters. Specific OATPs involved in DHEAS uptake are overexpressed in prostate cancer, leading to an increased intracellular availability of androgen precursors (Wright et al., 2011) and OATP polymorphisms are associated with time to progression during androgen deprivation therapy (Yang et al., 2011). Knock down of OATPs have also been shown to reduce the DHEAS-stimulated proliferation of prostate cancer cell lines (Arakawa et al., 2012). Once transported across the plasma membrane, a steroid sulfate ester is hydrolysed by steroid sulfatase (STS), with maintenance of stereo configuration yielding the respective hydroxysteroid that is subsequently accessible for enzymatic conversions or can exert biological functions (Hobkirk, 1993). STS is a membrane-bound enzyme on the luminal side of the endoplasmic reticulum (Ghosh, 2007) and ubiquitously expressed in all human tissues (Reed et al., 2005). Because of the high concentrations of circulating DHEAS one might assume that STS is a main gate keeper of peripheral androgen metabolism and action. However, while administration of DHEA yields significant increases in both DHEAS and active androgens (Arlt et al., 1998, 1999b), the administration of DHEAS does not result in any increase of DHEA and downstream androgens in healthy adults (Hammer et al., 2005). By contrast, patients with STS deficiency due to mutation show only a rather mild clinical phenotype with ichthyosis due to the accumulation of sulfated steroids in the skin. They present with a decreased DHEA/DHEAS ratio, which increases to normal levels after puberty, and a slightly increased androgen activation rate as peripheral 5 $\alpha$ -reductase activity seems to compensate for the loss of STS function (Idkowiak et al., 2016). STS may therefore rather function as a fine-tuning mechanism for intracellular free steroids. However, STS activity is upregulated in several types of cancer (reviewed in (Mueller et al., 2015)) and has been proposed as drug target in hormone-dependent breast, prostate and endometrial cancers to prevent local oestrogen (including 5-diol, which has oestrogenic effects) and androgen formation from estrone sulfate, DHEAS and 5-diol-sulfate. This mechanism has recently been shown to be of relevance also for colon cancer (Gilligan et al., 2017). The potential of STS inhibition has been evaluated in promising clinical trials (Geisler et al., 2011; Purohit and Foster, 2012; Thomas and Potter, 2015).

#### 4.2. Principles of intracrine androgen steroid metabolism


After cellular influx, an androgen precursor steroid is enzymatically activated by cell-specific enzymes and pathways before exerting its effect via the AR. Active androgens are subsequently inactivated enzymatically prior to being released from the cell for excretion. This concept of hormone action is termed “intracrinology” and is distinct from the classical concept of “endocrinology” with a designated gland secreting active hormones into circulation exerting direct effects on receptors in target tissues. Intracrinology is defined by the following principles: (1) Receptor (AR in case of androgens) and hormone precursors metabolising enzymes are co-expressed in the same cell; (2) an inactive hormone precursor (e.g. DHEAS, DHEA, A4, 11OHA4) is taken up from

circulation ( $\neq$  autocrinology); (3) each cell determines the amount of the active hormone (e.g. T, DHT, 11KT, 11KDHT) produced intracellularly by a specific set of enzymes; (4) several enzymatic steps are potentially involved in the production of the active hormone and represent different levels of regulation; (5) the hormone is enzymatically inactivated in the same cell prior to efflux; (6) no significant amount of active hormones are released from the cell into the extracellular space ( $\neq$  paracrinology) or circulation ( $\neq$  endocrinology) to prevent a systemic excess of active hormones (Labrie, 1991; Labrie et al., 1997a). Significantly, the metabolism of DHEA to active androgens reaches saturation with increasing circulating concentrations of DHEA, thereby protecting peripheral tissues from increased intracellular levels of androgens which may result from pathologically increased biosynthesis of androgen precursors in the adrenal (Labrie et al., 2007). Dysregulation of intracrine pathways can result from (1) alterations of expression leading to effects specific for the respective tissue or (2) mutations/polymorphisms of involved enzymes leading to systemic effects; and can be associated with metabolic dysfunction or sex steroid-dependent cancer as discussed below.

#### 4.3. Enzymes involved in intracrine androgen metabolism

Enzymatically catalysed reactions involved in the intracrine metabolism of C<sub>19</sub> steroids include hydrolysis of sulfate esters, oxidation of the 3 $\beta$ -hydroxyl followed by  $\Delta^{5-4}$ -isomerisation, 11 $\beta$ -oxidation/reduction, 17 $\beta$ -oxidation/reduction, stereoselective 5 $\alpha$ - or 5 $\beta$ -reduction of the  $\Delta^4$ -double bond, reduction of the 3-keto group, sulfation and glucuronidation of accessible hydroxyl groups. Additionally, C<sub>19</sub> steroids can serve as substrates for A-ring aromatisation yielding estrogens. HSD3B enzymes introduce the 3-keto- $\Delta^4$  motif into precursor androgens such as DHEA and 5-diol, while enzymes with reductive 17 $\beta$ HSD function convert the 17-keto group common in androgen precursors to a 17 $\beta$ -hydroxyl group. These two motifs (3-keto- $\Delta^4$  and 17 $\beta$ -hydroxyl) are shared by all active androgens (Fig. 5). In contrast to the adrenal and gonadal isoform, HSD3B2, which when deficient causes a variant of congenital adrenal hyperplasia, mutations in human HSD3B1, which is almost exclusively expressed in peripheral tissues and placenta (Labrie et al., 1992; Simard et al., 2005), are not known, probably as they would prevent placental PROG production during pregnancy (Miller and Auchus, 2011). AKR1C3 (HSD17B5) has been suggested to make the major contribution to peripheral A4 activation by conversion to T (Miller and Auchus, 2011). Certain polymorphisms of AKR1C3 are associated with PCOS and increased T levels in women (Ju et al., 2015). AKR1C3 is also overexpressed in prostate cancer, presumably promoting cancer progression by increasing intratumoral androgen levels (Adeniji et al., 2013; Fung et al., 2006).

Enzymes with 5 $\alpha$ -reductase activity can reduce the  $\Delta^4$ -double bond which, in the presence of the 3-keto and 17 $\beta$ -hydroxyl, leads to maximum androgen potential as is observed for DHT and 11KDHT (Pretorius et al., 2016). Systemic upregulation of 5 $\alpha$ -reductase activity is observed in women with PCOS leading to enhanced glucocorticoid clearance and enhanced androgen activation in peripheral tissues (Fassnacht et al., 2003; Stewart et al., 1990; Vassiliadi et al., 2009), which is associated with metabolic dysfunction (Conway et al., 2014; O'Reilly et al., 2014b). SRD5A2 encoding steroid 5 $\alpha$ -reductase type 2 (SRD5A2) is expressed in male reproductive tissues (Thigpen et al., 1993) and its disruption leads to the impairment of local DHT formation and in consequence disordered sex development in 46, XY individuals (Okeigwe and Kuohung, 2014; Wilson et al., 1993). The sequence of androgen activation is substrate specific as SRD5A enzymes can also reduce the  $\Delta^4$ -double bond of 17-keto steroids prior to their 17 $\beta$ -reduction.



**Fig. 5. Principles of androgen activation and inactivation.** All active androgens (T, DHT, 11KT and 11KDHT) share the 3-keto- $\Delta^4$  and 17 $\beta$ -hydroxyl motifs (shown in the black frame, taking example of T). Solid arrows indicate activation reactions, while dashed arrows represent inactivating reactions and preparation for excretion. 5 $\alpha$ -reduction is necessary to achieve maximum AR activation (DHT, 11KDHT). The 11-oxygenated androgens also require the conversion of the 11 $\beta$ -hydroxyl to the 11-ketone in order to obtain maximal activity (11KT and 11KDHT; dotted inset).

Indeed, the conversion of A4 ( $\Delta^4$ , 17-keto) to DHT (5 $\alpha$ , 17 $\beta$ ) proceeds via the 5 $\alpha$ -reduction of A4 to 5 $\alpha$ -androstane-3,17-dione (5 $\alpha$ -dione, 5 $\alpha$ -androstane-3,17-dione), followed by the conversion of 5 $\alpha$ -dione to DHT (Chang et al., 2011; Luu-The and Labrie, 2010; Samson et al., 2010) (Fig. 6). Conversely, our group has shown that the activation of 11KA4 ( $\Delta^4$ , 17-keto) proceeds by the 17 $\beta$ -reduction to 11KT, followed by 5 $\alpha$ -reduction to 11KDHT (5 $\alpha$ , 17 $\beta$ ) (Pretorius et al., 2017) (Fig. 6). It should also be noted that the expression of *HSD11B2*, which encodes the oxidative HSD11B isoform, is required for the activation of 11OHA4, which is the primary 11-oxygenated C<sub>19</sub> androgen precursor in circulation (Rege et al., 2013; Storbeck et al., 2013; Swart et al., 2013) (Table 2).

Fatty acid esters of androgen precursors can be hydrolysed intracellularly releasing the free steroid and fatty acid acylation of DHEA, 5 $\alpha$ -diol and T can take place in peripheral tissues, like adipose tissue (Hochberg, 1998; Vihma and Tikkanen, 2011; Wang et al., 2011, 2012).


Following activation, the resulting potent androgens are further metabolised in the target cell of androgen action, yielding inactive metabolites. This metabolism prevents the over-activation of the AR as well as the release of significant amounts of the activated androgens back into circulation (Labrie, 1991). As such the effect of the androgen precursors is maintained within a given target tissue and does not result in a systemic effect (Labrie, 1991; Labrie et al., 1997a). The inactivation reactions can be classified into phase 1 (oxidations and reductions at position 3 $\alpha$ / $\beta$ -, 5 $\alpha$ / $\beta$ -, 11 $\beta$ -, 17 $\beta$ -) and phase 2 metabolism (conjugation of 3/17-hydroxyls), according to the classical two-phase model of detoxification mechanisms (Williams, 1959). The main route of androgen inactivation proceeds (1) via the irreversible 5 $\alpha$ / $\beta$ -reduction of the 3-keto- $\Delta^4$  species,

followed by (2) the 3 $\alpha$ / $\beta$ -reduction of the 5 $\alpha$ / $\beta$ -reduced androgen. These steps may be followed by (3) the conjugation of the emerging 3-hydroxyl or the 17-hydroxyl (Fig. 5). Conjugation can also occur at the 17 $\beta$ -hydroxyl position and can occur prior to 3 $\alpha$ / $\beta$ - and 5 $\alpha$ / $\beta$ -reduction. Both 5 $\alpha$ / $\beta$ -reduction and glucuronidation are irreversible reactions and thus shift the equilibrium towards inactivation.

Unlike 5 $\alpha$ -reduction, 5 $\beta$ -reduction inactivates classical AR signalling capability of an androgen. Steroid 5 $\beta$ -reductase is a soluble aldo-keto-reductase enzyme (AKR1D1) and is presumed to be the only human enzyme catalysing the 5 $\beta$ -reduction of C<sub>18</sub>, C<sub>19</sub>, C<sub>21</sub>, and C<sub>27</sub> 3-keto- $\Delta^4$  steroids and bile acids (Chen et al., 2011; Chen and Penning, 2014; Kondo et al., 1994). It is mainly expressed in the liver (Charbonneau and The, 2001; Wu et al., 2009) and 5 $\beta$ -reduction therefore plays only a minor role in other tissues. 5 $\alpha$ -reduced metabolites are therefore conclusively more indicative for peripheral androgen metabolism than 5 $\beta$ -reduced metabolites, which are more likely to be of hepatic origin (Chen and Penning, 2014).

The 3 $\alpha$ - and 3 $\beta$ -reduction of 5 $\alpha$ / $\beta$ -reduced androgens is carried out by members of the AKR1C family, which exert 3 $\alpha$ - and 3 $\beta$ HSD activities (Penning et al., 2000, 2004; Steckelbroeck et al., 2004), with different isoforms showing distinct  $\alpha$ / $\beta$  preferences (Steckelbroeck et al., 2004). 5 $\beta$ -reduced androgens are preferably reduced to their 3 $\alpha$ -hydroxyl derivative (Jin et al., 2011) making 3 $\beta$ /5 $\beta$ -reduced androgens rare. "Back conversion" of a 3 $\alpha$ -reduced androgen to their 3-keto forms (e.g. 3 $\alpha$ -adiol to DHT) are possible in presence of an oxidative 3 $\alpha$ HSD; 3 $\alpha$ - and 3 $\beta$ -hydroxyls can also be interconverted by epimerase activity (Bauman et al., 2006; Belyaeva et al., 2007; Penning et al., 2004).

Androgen metabolites with a 3 $\alpha$ / $\beta$ - and/or 17 $\beta$ -hydroxyl can be



**Fig. 6. Schematic of intracrine pathways for the production of active androgens from  $C_{19}$  precursors.** Circulating  $C_{19}$  steroids (grey boxes) can be converted to active androgens (black boxes) in peripheral tissues exhibiting the required enzymatic activities. Activities are indicated next to each arrow. Pathways of peripheral androgen activation are recurring and distinct from pathways of *de-novo* biosynthesis (Figs. 2–4). 17 $\alpha$ HP, 5 $\alpha$ -pregnan-3 $\alpha$ ,17 $\alpha$ -diol-20-one; Pdione, 5 $\alpha$ -pregnan-17 $\alpha$ -ol-3,20-one.

conjugated using these hydroxyls for the esterification with either a glucuronosyl group or a sulfate. Conjugation of the 11 $\beta$ -hydroxyl has not been described, thus suggesting that it may not be accessible to the UDP-glucuronosyl transferases (UGT) or SULT enzymes. Glucuronidation of  $C_{19}$  steroids is performed by members of the UGT2B subfamily with different substrate preferences and regioselectivity (3 and/or 17), which are expressed in the liver and androgen-sensitive tissues (Belanger et al., 2003). UGTs are microsomal, membrane-bound enzymes catalysing the transfer of the glucuronic acid group of uridine diphospho-glucuronic acid to a functional group (here a hydroxyl) of a specific substrate. As opposed to sulfation, glucuronidation is irreversible and ultimately inactivates the androgen and initiates its renal excretion by increasing polarity and water solubility of the molecule (Belanger et al., 2003). UGT gene variants are associated with serum concentrations of glucuronidated androgen metabolites (Grant et al., 2013) and gene deletions of individual UGTs significantly reduce these concentrations (Nadeau et al., 2011), which is reflected in alterations of urinary T metabolite excretion (Jakobsson et al., 2006). Due to differential expression and regioselectivity of UGTs the comparative study of 3 $\alpha$ -adiol-3-glucuronide and 3 $\alpha$ -adiol-17-glucuronide can give insight in tissue-specific function of the different UGTs (Barbier and Belanger, 2008; Belanger et al., 2003). As *SULT2A1* expression is mainly limited to the liver, adrenal, colon and kidney (Riches et al., 2009), glucuronidation is the more important conjugation reaction in androgen target tissue. The two *SULT2B1* isoforms contribute to androgen metabolite sulfation in prostate, placenta, lung and skin (Falany et al., 2006).

Androgens may also be converted to oestrogens ( $C_{18}$  steroids with aromatic A-ring) in tissues expressing *CYP19A1* encoding cytochrome P450 aromatase (CYP19A1). CYP19A1 is a microsomal enzyme catalysing a 3-step  $C_{10}$ - $C_{19}$  demethylation/A-ring aromatisation of several  $C_{19}$  steroids via 19-hydroxy- and 19-aldehyd-intermediates (Beusen et al., 1987; Covey et al., 1987). A4, T, their 16 $\alpha$ -hydroxy derivatives and 16 $\beta$ OH-A4 are all substrates for this enzyme (Harada, 1988; Neunzig et al., 2017). Sites of extra-ovarian CYP19A1 expression are placenta, adipose tissue, brain, bone and vasculature (Simpson et al., 2002). The intracrine production of

oestrogens from androgen precursors is an essential source of oestrogens in postmenopausal women (Simpson, 2003).

The cell-specific pathways are determined by the respective set of enzymes expressed, their substrate specificities and enzymatic efficiencies, and the intracellular availability of free substrates. Directionality is driven by (1) irreversible reactions (5 $\alpha$ / $\beta$ -reduction, P450 oxidation, 3 $\beta$ -hydroxyl oxidation/ $\Delta^{5-4}$  isomerisation, glucuronidation), (2) the relative expression levels of reductive and oxidative HSD enzymes and (3) the redox status of the cell which contributes to HSD directionality (Agarwal and Auchus, 2005).

It should again be noted that care should be taken when using animal models to study intracrinology as the enzyme isoforms vary greatly between species. A good example are the significant differences between rodent and human HSD3B and HSD17B enzymes. Rodents have multiple isoforms of HSD3B, while humans have only two. Furthermore, unlike the human enzymes, some rodent HSD3B isoforms have additional 17 $\beta$ HSD activity (de Launoit et al., 1992; Payne et al., 1995; Simard et al., 1995). Similarly, HSD17B enzymes have different isoforms (Marchais-Oberwinkler et al., 2011; Moeller and Adamski, 2009), substrate specificities (Blanchard and Luu-The, 2007; Puranen et al., 1997) and tissue distribution (Martel et al., 1992) in humans and rodents. Enzymes with 3 $\beta$ HSD and 17 $\beta$ HSD activity are also insufficiently characterised in non-human primate models, therefore not allowing for comparisons to human intracrine systems to be drawn.

## 5. Pathways of peripheral androgen activation

### 5.1. The classical androgen biosynthesis pathway

Circulating T, generated from DHEA via A4, can be further activated to DHT in peripheral tissue with 5 $\alpha$ -reductase activity. While SRD5A1 catalyses the majority of hepatic 5 $\alpha$ -reduction, SRD5A2 in male reproductive tissues (Thigpen et al., 1993) and its deficiency leads to disorders of male sexual differentiation (Wilson et al., 1993). Circulating  $C_{19}$  precursors can also be activated by 3 $\beta$ HSD and reductive 17 $\beta$ HSD activity leading to the formation of T. However, the classical pathway via T plays only a minor role in the

generation of DHT from inactive C<sub>19</sub> precursors.

It is worth noting that a third isoform of steroid 5 $\alpha$ -reductase (SRD5A3) has been described (Cantagrel et al., 2010; Mitsiades et al., 2012; Uemura et al., 2008) and is expressed in peripheral tissue (Yamana et al., 2010). While the role of SRD5A3 in androgen metabolism is yet to be fully elucidated, SRD5A3 has confirmed polyprenol reductase activity and has been shown to be involved in N-linked glycosylation with SRD5A3 mutations being linked to congenital disorders of glycosylation (Cantagrel et al., 2010).

### 5.2. The alternate 5 $\alpha$ -dione pathway

The alternate 5 $\alpha$ -androstanedione pathway bypasses T as intermediate of DHT biosynthesis (Fig. 6). A4 is first 5 $\alpha$ -reduced by SRD5A1, yielding 5 $\alpha$ -dione due to the higher affinity and catalytic efficiency of SRD5A1 for A4 than for T (Andersson and Russell, 1990; Russell and Wilson, 1994; Sugimoto et al., 1995), which is followed by the conversion of 5 $\alpha$ -dione to DHT by reduction of the 17-ketone (Chang et al., 2011; Luu-The and Labrie, 2010; Samson et al., 2010). This pathway is not present in the adrenal or gonads, but plays the major role for peripheral DHT generation from circulating precursors other than T (Luu-The and Labrie, 2010). It has especially been shown to be an essential pathway for intratumoral DHT production from adrenal androgen precursors in CRPC when circulating levels of T are significantly reduced by physical or chemical castration (Chang et al., 2011; Sharifi and Auchus, 2012).

### 5.3. The backdoor pathway

Another alternative pathway to DHT is the so-called “backdoor” pathway which by-passes T, A4 and DHEA. In this pathway, C<sub>21</sub> precursors, mainly 17 $\alpha$ -hydroxyprogesterone (17OHPROG) but also progesterone, are substrates for (1) 5 $\alpha$ -reductase activity and (2) a reductive 3 $\alpha$ HSD activity. This leads to generation of 5 $\alpha$ 17-hydroxypregnanolone (5 $\alpha$ 17HP; 5 $\alpha$ -pregnan-3 $\alpha$ ,17 $\alpha$ -diol-20-one) in the case of 17OHPROG, which then (3) undergoes the 17,20-lyase reaction to androsterone (AST) (Auchus, 2004). Reductive 17 $\beta$ HSD activity (4) and oxidative 3 $\alpha$ HSD activity (5) subsequently lead to the conversion of AST to DHT (Fig. 6). The initial 5 $\alpha$ - and 3 $\alpha$ -reductions support the C<sub>17</sub>-C<sub>20</sub> side-chain cleavage by delivering 5 $\alpha$ 17HP, which is the best substrate for the 17,20-lyase activity of CYP17A1 and whose cleavage is not dependent on cytochrome b<sub>5</sub> (Gupta et al., 2003). In humans, the backdoor pathway is relevant in pathological conditions when 17OHPROG accumulates, such as in congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency (PORD) or 21-hydroxylase deficiency (Arlt et al., 2004; Homma et al., 2006; Kamrath et al., 2012; Krone et al., 2012; Miller and Auchus, 2011). In PORD, the alternative pathway can result in sufficient virilisation of affected 46, XY individuals in the prenatal period, despite the complete disruption of the classic androgen pathway, as CYP17A1 will still convert 5 $\alpha$ 17HP towards DHT but no longer 17 $\alpha$ -hydroxy-pregnenolone and 17OHPROG to DHEA and A4, respectively.

### 5.4. The 11-oxygenated androgen pathways

Pathways for the generation of active 11-oxygenated androgens (11KT and 11KDHT) start with the CYP11B1 catalysed 11 $\beta$ -hydroxylation of A4 and T (Swart et al., 2013). The adrenal is the only source for 11-oxygenated C<sub>19</sub> precursors due to the adrenal specific expression of CYP11B1. It is not surprising that 11OHA4 is the predominant 11-oxygenated C<sub>19</sub> steroid produced as the adrenal produces significantly more A4 than T (Rege et al., 2013). Both

11OHA4 and 11OHT are released into circulation and can subsequently be activated in peripheral tissues (Fig. 6). Both steroids can be converted to their respective 11-keto forms by HSD11B2. While 11OHA4 is not a substrate for reduction of the 17 $\beta$ -hydroxyl, 11KA4 is readily converted to 11KT which can be 5 $\alpha$ -reduced to 11KDHT (Bloem et al., 2013; Pretorius et al., 2017; Swart and Storbeck, 2015). While 11OHT and 11OHDHT represent partial AR agonists, 11KT and 11KDHT are full agonists with the same AR activating potential as T and DHT, respectively (Pretorius et al., 2016; Storbeck et al., 2013). The presence of the reductive enzyme HSD11B1, in some peripheral tissues may therefore prevent the activation of 11OHA4 and catalyse the inactivation of 11KA4 and 11KT, which are also in circulation, albeit at significantly lower levels than 11OHA4 (O'Reilly et al., 2016). The relative activities of HSD11B2 and HSD11B1 are therefore critical in determining the activity of 11-oxygenated androgens in peripheral tissue. This additional level of regulation suggests that the 11-oxygenated androgens have a more select number of target tissues in comparison to the classical androgens.

## 6. Directionality of biosynthetic steps, phase 1 metabolism and conjugation

The classical concepts of androgen biosynthesis and metabolism suggest that conjugation is the final step of a pathway. For example, DHEA is sulfated by SULT2A1 to DHEAS at the end of adrenal androgen biosynthesis, and detoxification is achieved by sequential phase 1 and 2 metabolism; with the phase 1 reaction sometimes even being required to allow a phase 2-reaction, e.g. the reduction of the 3-ketone to give a hydroxyl accessible for conjugation. However, increasing evidence suggests that this directionality is not obligate.

A small number of enzymatic pathways have been described that can directly interconvert sulfated steroids and proceed analogously to the biosynthetic pathways of free androgens. DHEAS has been shown to be converted to 5-diol-3 $\beta$ -sulfate by 17 $\beta$ HSD activity present in human testes (Ruokonen, 1978) and T-sulfate has been shown to be converted to estradiol-17-sulfate by CYP19A1 in human placental microsomes (Satoh et al., 1992). Furthermore, CYP17A1 has been shown to be able to 17 $\alpha$ -hydroxylate PREG-sulfate in a recombinant human cell line, but could not catalyse the subsequent 17,20-lyase reaction (Neunzig et al., 2014). Interestingly, recombinant HSD3B2 has been shown to have steroid sulfatase activity converting PREG-sulfate to PREG (Sanchez-Guijo et al., 2016). Although a physiological meaning of these reactions has not been established, their discovery clearly shows an underestimated role of sulfated steroids in steroid metabolism and action.

Interestingly, phase 2 reactions can precede phase 1 reactions during androgen inactivation. After glucuronidation and sulfation androgen metabolites can be metabolised by AKR1C subfamily members, e.g. DHT-17-glucuronide/sulfate to 3 $\alpha$ -adiol-17-glucuronide/sulfate with kinetic parameters even indicating a preference of the 17-glucuronidation preceding the 3 $\alpha$ -reduction (Jin et al., 2009; Penning et al., 2010). Finally, foetal CYP3A7 has been shown to catalyse the 16 $\alpha$ -hydroxylation of DHEAS (Ohmori et al., 1998).

## 7. Intracrinology in metabolic target tissues

### 7.1. Adipose tissue

Adipose tissue expresses isoforms of all enzymes required for the activation of androgens from circulating precursors (STS,



HSD3B1, reductive 17 $\beta$ HSDs, namely HSD17B1, HSR17B3 and AKR1C3 with involvement in androgen activation, and SRD5A1) as well as their subsequent inactivation (reductive 3 $\alpha$ HSDs (mainly AKR1C2), UGT2B15 and UGT2B17) (Blouin et al., 2009b; O'Reilly et al., 2014a; Tchernof et al., 2015). The activation of androgens within adipocytes has been shown to regulate proliferation and differentiation, insulin sensitivity, adipokine signalling and lipid metabolism (O'Reilly et al., 2014a). While functional studies of androgen conversion within adipocytes are fragmentary, there is evidence for the importance of HSDs from the AKR1C subfamily. AKR1C1 (predominant 20 $\alpha$ HSD with low reductive 3 $\alpha$ HSD activity), AKR1C2 (reductive 3 $\alpha$ HSD activity) and AKR1C3 (reductive 17 $\beta$ HSD activity) show the highest expression levels of all steroid converting enzymes expressed in adipocytes of women and men (Blouin et al., 2009b) and their expression and activity correlates with obesity in women and men (Blouin et al., 2005, 2006). AKR1C3 expression has been shown to decrease with weight loss in female subcutaneous adipose tissue (Quinkler et al., 2004). AKR1C3 (reductive 17 $\beta$ HSD, A4 $\rightarrow$ T) and AKR1C2 (reductive 3 $\alpha$ HSD, DHT $\rightarrow$ 3 $\alpha$ -adiol) activity has been shown for adipocytes from both men and women with higher activity of the inactivating 3 $\alpha$ HSD (Blouin et al., 2003, 2006). The correlation of both activating and inactivating enzymes with obesity indicates an increased local production and metabolic clearance of androgens highlighting the importance of adipose tissue intracrinology in obesity. Measurements of sex steroid levels in adipose tissue of obese men (ng/g) revealed general levels of DHEA > A4  $\geq$  T > E1 > DHT with differences between omental and subcutaneous depots (Belanger et al., 2006). The approximation of A4 and T levels compared to circulating concentrations highlights the importance of reductive 17 $\beta$ HSD activity (AKR1C3) converting A4 to T local androgen load (Belanger et al., 2006). Importantly, AKR1C3 expression and activity increases with the differentiation of preadipocytes to mature adipocytes and the interconversion of A4 and T is shifted in favour of T generation only in mature adipocytes (Quinkler et al., 2004). The expression of UGTs in adipose tissue (Tchernof et al., 1999) and the correlation of plasma 3 $\alpha$ -adiol glucuronide with fat mass in men (Tchernof et al., 1997) suggest phase 2 metabolism as final step of androgen inactivation in adipocytes.

Androgen excess is recognised as the major determinant driving metabolic dysfunction observed in women with PCOS (Conway et al., 2014) and the degree of androgen excess correlates with the severity of insulin resistance in PCOS (O'Reilly et al., 2014b). We have recently shown that serum T levels correlated with BMI in both healthy women and women with PCOS. This data supports the AKR1C3 catalysed conversion of A4 to T within adipose tissue and further suggests that not all T produced within adipocytes is inactivated, but that a portion of the T is also released in circulation. Interestingly, we also showed that in the same cohort 11KT did not correlate with BMI, which is not surprising given that HSD11B1 is present in adipose tissue, and not HSD11B2. This prevents the conversion of 11OHA4 to 11KA4, which is a prerequisite for the subsequent conversion of 11KA4 to 11KT by AKR1C3 (O'Reilly et al., 2016).

Aromatisation of androgens to oestrogens takes place in male and female adipose tissue (Longcope et al., 1978; McTernan et al., 2000) and increased aromatization has been proposed as a major mechanism leading to obesity-induced male androgen deficiency (Cohen, 1999). The expression of aromatase in adipose tissue has also been shown to be elevated in postmenopausal women (Bulun and Simpson, 1994) and as such adipose tissue is an important source of oestrogen in these women (Simpson, 2003). The effects of androgens on adipocyte function and the expression pattern of metabolizing enzymes are defined by sex, fat depot localisation and menopause status (Blouin et al., 2009a; O'Reilly et al., 2014a;

Quinkler et al., 2004).

## 7.2. Skeletal muscle

Androgens exhibit beneficial effects on skeletal muscle function supporting myogenic differentiation and improving protein synthesis, lipid oxidation, insulin sensitivity, glucose utilisation and mitochondrial function (Kelly and Jones, 2015). Furthermore, muscle regeneration and recovery is supported by the androgen-dependent regulation of muscle satellite cells (MacKrell et al., 2015). As a consequence of their higher circulating T levels, men have higher lean mass than women (Wells, 2007). Muscle cells exhibit 3 $\beta$ HSD, reductive 17 $\beta$ HSD and 5 $\alpha$ -reductase activity resulting in the activation of DHEA to T and DHT. Expression decreases during ageing and can be rescued by resistance training (Sato et al., 2014a, 2014b). The production of T from A4 by AKR1C3 has been proposed to be the essential step of androgen activation in muscle (Lin et al., 1997; Longcope and Fineberg, 1985; Luu-The and Labrie, 2010), with the further conversion of T to DHT seeming to play only a minor role as there is no clarity regarding the expression of SRD5A isoforms (Luu-The and Labrie, 2010). A4 and T can also be aromatised in skeletal muscle (Longcope et al., 1978; Matsumine et al., 1986), with low activity and expression of aromatase. However, as skeletal muscle represents a major part of the human body, its contribution to systemic oestrogen levels has been proposed to be significant in men and post-menopausal women (Larionov et al., 2003). 3 $\alpha$ -reduction and phase 2 metabolism in skeletal muscle has not been studied to date and the contribution of skeletal muscle to circulating levels of active androgens cannot conclusively be ruled out at present. No mRNA of SULT2A1 or SULT2B1 has been detected in skeletal muscle (He et al., 2005; Luu-The et al., 1995).

## 7.3. Liver


### 7.3.1. Hepatic phase 1 metabolism

The liver catalyses extensive phase 1 and phase 2 metabolism of xenobiotics and endogenous hormones including steroids, thereby regulating their activity and clearance. Hepatic phase 1 metabolism of androgens includes the following types of reactions: (1) 5 $\alpha$ / $\beta$ -reduction of the  $\Delta^4$ -double bond followed by 3 $\alpha$ / $\beta$ -reduction of the 3-ketone; (2) oxidations by a large set of hepatic P450 enzymes; (3) HSD reactions of 11 $\beta$ - and 17 $\beta$ -hydroxyls if available and of hydroxyls introduced by P450s. Fig. 7 provides a summary of reactions catalysed by drug- and xenobiotic-metabolising liver enzymes.

The liver has high levels of the 5 $\beta$ -reductase AKR1D1 and primarily produces 5 $\beta$ -reduced androgens (e.g. etiochonanalone, 5 $\beta$ -androstan-3 $\alpha$ -ol-17-one, ETIO) in contrast to peripheral tissue which produce 5 $\alpha$ -reduced species (Charbonneau and The, 2001; Chen and Penning, 2014; Penning, 2010). The subsequent formation of the 3 $\alpha$ -reduced counterpart of a 5 $\beta$ -reduced steroid is favoured over the 3 $\beta$ -reduction leading to mainly 3 $\alpha$ OH-5 $\beta$ -reduced metabolites (Jin et al., 2011). Mutations of AKR1D1 lead to severely reduced to completely absent urinary 5 $\beta$ -reduced steroid excretion and hepatic failure, as AKR1D1 is essentially involved in hepatic bile acid synthesis, but no other clinical manifestations (Gonzales et al., 2004; Lemonde et al., 2003; Palermo et al., 2008).

Hepatic phase 1 metabolism is extremely diverse due to the contribution of various P450 enzymes. In contrast to the steroidogenic P450s expressed in adrenals and gonads, hepatic CYPs have a high degree of functional plasticity on different levels: (1) genetic variation (polymorphisms, copy number, promoter variants); (2) variation of expression levels due to inducibility by e.g. xenobiotics; (3) variation of activity (broad substrate specificity and thus competition of different substrates, limited selectivity, multiple substrate binding sites positively or negatively influencing the





**Fig. 7. Overview of hepatic phase 1 and 2 metabolism of C<sub>19</sub> steroids.** Phase 1 metabolism comprises the 5 $\alpha$ / $\beta$ -reduction of the  $\Delta^4$  double bond and the reduction of the 3-keto group to its 3 $\alpha$ / $\beta$ -hydroxyl as well as hydroxylations and further oxidations at various positions. Phase 2 reactions consist of the conjugation of the 3- and 17-hydroxyls. 17 $\alpha$ -conjugates originate from Epitestosterone. The reactions shown in the figure summarize those described for T, A4 and DHEA.

active site, influence of the allosteric modulator cytochrome *b*<sub>5</sub> and competition for their electron transfer protein cytochrome P450 reductase) (Zanger and Schwab, 2013). This leads to high inter- and intra-individual variability in hepatic P450 enzyme activity. About a dozen P450s of the CYP1, CYP2, CYP3 and CYP7 families can catalyse hydroxylations with diverse regio- and stereochemistry as depicted in Fig. 7 and summarized in a review by Niwa et al. (2015). Some of these P450s may also catalyse an additional oxidation of a hydroxyl to its ketone (e.g. T  $\rightarrow$  A4 or 16 $\beta$ OH-T  $\rightarrow$  16-keto-T). CYP3A4 is the most abundant P450 in the liver (~30%) (Shimada et al., 1994) and predominantly, though not exclusively, catalyses the 6 $\beta$ -hydroxylation of T and the 16 $\alpha$ - and 7 $\alpha$ -hydroxylation of DHEA (Niwa et al., 2015).

Several HSD17B isoforms are active in the liver (Moeller and Adamski, 2009) as well as HSD11B1, which oxidises 11-keto-steroids to their 11 $\beta$ -hydroxyl form. HSD11B1 plays an important role in the recycling of cortisol from its inactive metabolite cortisone (Gathercole et al., 2013) and might therefore also be involved in the hepatic metabolism of 11-oxygenated androgens. HSD11B1 is also involved in the metabolism of the DHEA metabolite 7 $\alpha$ OH-DHEA (produced by CYP3A4 and CYP7B1) (El Kihel, 2012). It catalyses the interconversion of 7 $\alpha$ - and 7 $\beta$ -OH-DHEA via the 7-keto intermediate (Muller et al., 2006).

Unusual reactions leading to new T metabolites have recently been described and include the methylation of an unknown T metabolite, probably at a hydroxyl functional group, and the demethylation to C<sub>19</sub>-nor-androgens (Piper et al., 2016). The excretion of 19-nor-AST has previously been described (Dehennin et al., 1999). De-methylation may result from uncomplete C<sub>10</sub>, 19-lyase/A-ring aromatisation reaction by CYP19A1.

### 7.3.2. Hepatic phase 2 metabolism

Hepatic phase 2 metabolism includes glucuronidation and sulfation. All UGTs capable of androgen glucuronidation are expressed at high levels in the liver (Belanger et al., 2003) leading to intensive hepatic glucuronidation compared to other tissues (Rittmaster et al., 1993). Conjugated metabolites are released from liver cells into circulation by active transport. The main androgen metabolites in circulation derived from hepatic and other peripheral metabolism are 3 $\alpha$ -adiol-3-glucuronide, 3 $\alpha$ -adiol-17-glucuronide, AST-glucuronide and ETIO-glucuronide with levels higher than for T. Interestingly, the concentration of 17-keto metabolites in

circulation is higher than that of the 17 $\beta$ -hydroxy metabolites with AST-glucuronide and -sulfate being the most abundant (see (Kalogera et al., 2013) for a review of LC-MS/MS based studies of circulating androgen and their glucuronides).

Genetic variations of UGTs can change the glucuronidation efficiency for an androgen and alter its excretion (Piper et al., 2016). The formation of androgen linked di-glucuronides (second glucuronidation occurs on the first glucuronosyl moiety) is also possible (Murai et al., 2005, 2006). Discrete di-glucuronidation (conjugation at two different functional groups of the same molecule) has to our knowledge not been described. Steroids are preferentially glucuronidated in either 3- or 17-position depending on the substrate and regio selectivity of the individual UGTs.

The liver also shows high SULT expression and activity compared to other tissues, including *SULT2A1* and *SULT2B1* involved in androgen metabolism (Meloche and Falany, 2001; Riches et al., 2009). The formation of distinct di-sulfates is described for the synthetic androgen tibolone (Falany et al., 2004) and cholesterol (Cook et al., 2009). 16 $\alpha$ -hydroxy-DHEAS, 5-diol-sulfate, AST-sulfate, EpiAST-sulfate can be measured in nM concentrations in serum of both men and women (Labrie et al., 1997b; Sanchez-Guijo et al., 2015; Zang et al., 2017). Importantly, women produce androgen metabolites in concentrations comparable to that of men (Labrie et al., 1997b; Trabert et al., 2016; Zang et al., 2017).

### 7.3.3. The liver as a target tissue of androgen action

Although the liver is traditionally considered only in terms of phase 1 and phase 2 metabolism, the liver also expresses AR turning it into a target tissue for classical androgen action. Both T and DHT have recently been shown to increase lipogenesis in human hepatocytes of female (but not male) donors (Nasiri et al., 2015) and androgens have been shown to play a crucial role in the development of hepatocellular carcinoma (Kalra et al., 2008; Kanda et al., 2014).

## 8. Intracrine androgen metabolism in reproductive target tissues

### 8.1. Breast and endometrium

While oestrogens have essential proliferative effects on the

normal mammary gland and breast cancer, androgens and the expression of the AR have demonstrated both positive and negative outcomes in breast cancer as reviewed in (Hickey et al., 2012; McNamara and Sasano, 2015a, 2016). Both androgens and oestrogens are synthesised from circulating androgen precursors in breast tissue and the homeostasis of these pathways determines health status (McNamara and Sasano, 2015b). Aromatase inhibition is a mainstay of postmenopausal breast cancer treatment and an impressive model for the translation of intracrine modulation to patient care. Androgen metabolism in breast is however, frequently overlooked. Numerous studies have shown that androgen levels are higher within breast tissue than in circulation and are generally higher in benign tissue than cancerous tissue, demonstrating the relevance of intracrinology in breast and its dysregulation in cancer (Stanczyk et al., 2015). It should also be noted that menopausal status significantly influences the intracrinology of breast tissue (McNamara and Sasano, 2015b). Breast cancer tissue has STS, 3 $\beta$ HSD, reductive 17 $\beta$ HSD, 5 $\alpha$ -reductase and aromatase activities (Labrie et al., 2003; McNamara and Sasano, 2015b; Suzuki et al., 2005) as well as 3 $\alpha$ HSD, UGT, and SULT activity (McNamara et al., 2013). Selective inhibition of HSD3B1 has been shown to slow down proliferation of breast cancer cell line and might just represent an interesting drug target simultaneously tackling androgen and oestrogen synthesis (Thomas et al., 2011). However, as with the heterogeneous expression of steroid receptors within breast cancer the expression of steroid metabolising enzymes is also heterogeneous and the specific pathways followed can therefore vary greatly. The detailed intracrinology of breast tissue is therefore a complex topic and beyond the scope of this review for review see (Africander and Storbeck, 2017; Capper et al., 2016; Labrie et al., 2003; McNamara et al., 2013; McNamara and Sasano, 2015b).

In the endometrium, intracrine production of androgens and estrogens may be involved in regulating decidualisation (transformation of endometrial stromal cells to secretory cells) and receptivity. While aromatase activity increases during decidualisation leading to an increased estrogen secretion (Gibson et al., 2013), time-dependent changes in *SDR5A1* and *AKR1C3* expression alter T and DHT secretion. While T production increases and stays elevated during decidualisation due to constantly increased *AKR1C3* levels, DHT secretion initially increases, but then decreases with the progression of the decidualisation process following reductions in *SDR5A1* levels (Gibson et al., 2016).

## 8.2. Prostate

Androgens and in particular the intraprostatic conversion of circulating T to DHT by *SDR5A2* (Russell and Wilson, 1994) are required for normal prostate development and function (Andersson et al., 1991; Imperato-McGinley et al., 1974). Androgen deprivation therapy in the form of chemical or physical castration is therefore a preferred treatment of advanced prostate cancer. Despite initially demonstrating excellent results the prostate cancer often reemerges as castration resistant prostate cancer, which in most cases remains androgen dependent. While the contribution of *de-novo* intratumoral biosynthesis to local androgens has mostly been excluded (Hofland et al., 2010), numerous studies have shown that CRPC is dependent on the intracrine conversion of circulating androgen precursors of adrenal origin to active androgens reviewed in (Capper et al., 2016; Luu-The et al., 2008; Pretorius et al., 2017; Sharifi and Auchus, 2012). Specifically, the alternate 5 $\alpha$ -dione pathway catalyses the conversion of DHEA and A4 to DHT while bypassing T completely (Fig. 6). The flux through this pathway is due to the preference of *SDR5A1*, the dominant isoform expressed in CRPC, for A4 over T, coupled to the poor efficiency by which *AKR1C3* converts A4 to T (Chang et al., 2011; Sharifi, 2012).

Additionally, the back conversion of 3 $\alpha$ -adiol to DHT by oxidative 3 $\alpha$ HSDs has been demonstrated for prostate cancer cell lines enabling a recycling of this DHT metabolite (Bauman et al., 2006; Mohler et al., 2011; Rizner et al., 2003). Prostate cells also express CYP3A4 that can inactivate T by conversion to mainly 6 $\beta$ OH-T (with 2 $\beta$ -, 15 $\alpha$ / $\beta$ - and 11 $\beta$ -hydroxyl side product formation (Niwa et al., 2015)) and a decrease of CYP3A4 expression is observed in prostate cancer (Fujimura et al., 2009). After 5- and 3-reduction androgens are extensively glucuronidated in the prostate producing 3 $\alpha$ -adiol-17-glucuronide and AST-3-glucuronide. Genetic variations of UGTs significantly contribute to prostate cancer risk and progression and there is evidence for a down-regulation of UGTs in prostate cancer promoting intratumoral androgen accumulation (Barbier and Belanger, 2008; Gauthier-Landry et al., 2015). Because of the ability of prostate cancer cells to convert 3 $\alpha$ -adiol back to DHT its glucuronidation is of particular importance for androgen inactivation and the regulation of cancer progression (Chouinard et al., 2007).

Recent studies have also shown that prostate cancer cell lines are able to metabolise the adrenal androgen precursor 11OHA4 (Storbeck et al., 2013; Swart et al., 2013; Swart and Storbeck, 2015). Metabolism proceeds via the conversion of 11OHA4 to 11KA4 by HSD11B2. 11KA4 is then preferentially converted to 11KT by *AKR1C3* and 11KT can then be 5 $\alpha$ -reduced to yield 11KDHT (Pretorius et al., 2017) (Fig. 6). Interestingly, the rate at which 11KT and 11KDHT are inactivated by prostate cancer cell lines has been shown to be significantly lower than for T and DHT, suggesting that these metabolites may remain active for longer than the classical androgens (Pretorius et al., 2016). Significantly, both 11KT and 11KDHT have been shown to be able to induce androgen-regulated gene and protein expression as well as cell growth in androgen dependent prostate cancer cell lines suggesting that these androgens may play a previously overlooked, but important role in the development and progression of CRPC (Pretorius et al., 2016). Indeed, a recent study showed that the levels of these 11-oxygenated androgens were higher than those of the classical androgens in tissue from two patients with prostate cancer (du Toit et al., 2017). Despite the promising results obtained in these initial studies, much work is still required to elucidate the contribution of these androgens to CRPC.

## 8.3. Placenta

The placenta expresses *CYP11A1* and catalyses StAR-independent (Sugawara et al., 1995) *de-novo* steroidogenesis probably facilitated by MLN64 with StAR-like activity (Bose et al., 2000). *De-novo* steroidogenesis in the placenta yields mainly PREG and PROG due to low levels of CYP17A1. However, CYP17A1 activity is sufficient for the production of T, E1 and E2, as has been demonstrated for trophoblasts (Escobar et al., 2011). In addition, the placenta possesses the enzymatic machinery capable of converting C<sub>19</sub> steroids derived from the foetal adrenal and liver (DHEAS and 16 $\alpha$ OH-DHEA, respectively) to oestrogens during their transplacental passage (Miller and Auchus, 2011). This mechanism protects the mother (and female foetus) from virilisation by the high concentrations of C<sub>19</sub> steroid released into circulation by the foetal adrenal (Conte et al., 1994). However, 5 $\alpha$ -reduced androgens cannot be aromatised and therefore can transfer from fetus to mother unhindered by the placenta, which is observed e.g. in aromatase deficiency and PORC. C<sub>19</sub> steroid conversion in the placenta thus has a protective systemic function rather than an intracrine function.

## 9. Intracrine androgen metabolism in other tissues

### 9.1. Skin

Several cellular components of the interfollicular epidermis and pilosebaceous unit have the capability of *de-novo* steroid biosynthesis supported by StAR activity (Anuka et al., 2013). The resulting steroids include glucocorticoids and androgens and these pathways were reviewed in (Labrie et al., 2000; Nikolakis et al., 2016; Slominski et al., 2013). C<sub>19</sub> steroids are produced from cutaneous cholesterol via the classical  $\Delta^5$  pathway. Circulating DHEA can also be used as a precursor to produce active androgens by 3 $\beta$ HSD, 5 $\alpha$ -reductase and reductive 17 $\beta$ HSD activity (Nikolakis et al., 2016; Slominski et al., 2013). In fact, studies with cultured sebocytes suggest that circulating DHEA may be the more important source of androgen precursors (Chen et al., 2010). Local androgen availability in the skin is necessary to stimulate sebum secretion and hair growth. The generation of DHT is essential for beard growth (Diamond et al., 1996; Messenger, 1993). Functional comparison of different epidermal cell types hint at differential functions for androgen biosynthesis and inactivation (Fritsch et al., 2001).

The presence of SRD5A1 allows for the local production of DHT (Luu-The et al., 1994), with the 5 $\alpha$ -dione pathway bypassing T being the preferred route (Samson et al., 2010; Sugimoto et al., 1995) (Fig. 6). Acne vulgaris and androgenic alopecia are associated with local androgen hyperproduction. Acne-prone skin expresses higher levels of androgen generating enzymes than non-acne-prone skin (HSD17B3 and AKR1C3 converting A4 to T, STS and SRD5A1; summarized in (Nikolakis et al., 2016)). Local over-production of DHT has been proposed as cause of androgenic alopecia (Lee et al., 2015; Sawaya and Price, 1997) and 5 $\alpha$ -reductase inhibitors are an established treatment for male pattern alopecia (Kaufman and Dawber, 1999).

In the skin, A4 and T can be aromatised to oestrogens, which induce beneficial effect on keratinocyte proliferation, production of extracellular matrix components and wound healing (Kanda and Watanabe, 2004a, 2004b; Raine-Fenning et al., 2003). Downstream metabolites of DHT are AST and 3 $\alpha$ -adiol and the back conversion of the 3 $\alpha$ -reduced metabolites is also possible. UGTs and SULTs are expressed and may contribute to phase 2 metabolism (Slominski et al., 2013). In addition, DHEA can be 7 $\alpha$ -hydroxylated by CYP7B1, which is expressed in the skin (Hennebert et al., 2007), thereby preventing its metabolism to active androgens.

### 9.2. Salivary gland

Steroid measurements in saliva can be superior to that of serum as they rely on a non-invasive, cheap collection technique and are representative of the bioavailable, non-protein bound, levels of the steroid that can passively diffuse from circulation into saliva in the salivary glands (Vining et al., 1983). A range of liquid chromatography tandem mass spectrometry assays for salivary cortisol/cortisone and salivary androgens have thus been developed and implemented in routine clinical laboratories (Keevil, 2016). It is therefore essential that steroid metabolism in the salivary glands, which often lead to altered concentrations in saliva compared to serum concentrations, are understood in detail to correctly interpret salivary steroid concentrations in their systemic context. Salivary glands express STS, SULT2B1, HSD3B1, AKR1C3, SRD5A1 and CYP19A1 and the activity of the encoded enzymes allows for the conversion of circulating DHEAS and DHEA to DHT and oestrogens (Spaan et al., 2009). Low local HSD3B1 expression coupled to derangement of subcellular compartmentalization have been suggested to lead to impaired 5 $\alpha$ -reductase activity in Sjogren's syndrome resulting in local DHT deficiency and oestrogen excess, as

reflected by salivary concentrations (Kontinen et al., 2015; Porola et al., 2008; Spaan et al., 2009). However, *in-vitro* studies with homogenised submandibular and parotid glands showed a preference for oxidative 17 $\beta$ HSD activity (T  $\rightarrow$  A4 etc.) (Blom et al., 1993; Djoseland et al., 1982). Oxidative HSD11B2 is present in the parotid gland (Hirasawa et al., 1997; Smith et al., 1996) resulting in a significantly higher cortisone/cortisol ratio in saliva than in serum (Hawley and Keevil, 2016) and might thus also affect the ratio of 11-keto to 11 $\beta$ -hydroxy androgens.

## 10. Kidney androgen metabolism and renal excretion of androgens

### 10.1. The kidney as an androgen-metabolising organ

Surprisingly the kidney has been shown to be able to catalyse the biosynthesis of active androgens using PREG as precursor for DHEA production by CYP17A1 (Quinkler et al., 2003). DHEA could be further metabolised to T, via A4 or 5 $\alpha$ -dione, and the resulting T could be 5 $\alpha$ -reduced to DHT. Additionally, the expression of genes (AKR1D1 and AKR1C2) encoding enzymes contributing to phase 1 metabolism and inactivation of androgens have been demonstrated (Quinkler et al., 2003). It should, however, be noted that the tissue used in this study was derived from tumour nephrectomies, thus bringing into question the relevance of these results to the healthy kidney. The kidney may be the major site of the generation of the T 17 $\alpha$ -epimer "epitestosterone" (EpiT, 17 $\alpha$ -hydroxytestosterone), which has weak antiandrogenic functions and may inhibit certain steroidogenic enzymes. EpiT circulates with low nM concentrations and EpiT/T ratios are between 0.1 for women and up to 1 in men as measured in serum of healthy subjects by immunoassay (Havlikova et al., 2002). The ratio of urinary T and EpiT-glucuronide is used as an indicator of exogenous T administration in doping analysis (Mareck et al., 2010; Shackleton et al., 1997a, 1997b; Wada, 2015). Given its high concentrations, the physiological effects of EpiT requires further research. Furthermore, it is possible that current LC-MS/MS assays used for the determination of serum T might erroneously include EpiT in their T measurements due to limited resolution. While there is no interconversion of T and EpiT excluding T as the direct precursor to EpiT, a reductive 17 $\alpha$ HSD (product of AKR1C21) has been isolated from the mouse and has been shown to convert 17-keto steroids to their 17 $\alpha$ -hydroxyl, thus suggesting that A4 could be the direct precursor to EpiT. This enzyme was specifically expressed in the mouse kidney (Bellemare et al., 2005). Excreted metabolites of EpiT are 5 $\alpha$ - and 5 $\beta$ -androstane-3 $\alpha$ ,17 $\alpha$ -diols (Piper et al., 2009; Shackleton et al., 1997b; Wilson and Lipsett, 1966). Elimination of EpiT thus follows the same pathways as T.

The kidney has high levels of HSD11B2 activity which protects the mineralocorticoid receptor from activation by cortisol by inactivating it to cortisone (Edwards and Stewart, 1991; Funder et al., 1988). The kidney is therefore also likely a site of the conversion of 11-hydroxy C<sub>19</sub> steroids to their corresponding 11-keto forms. Significantly, it is the 11-keto C<sub>19</sub> steroids that are more androgenic than their 11-hydroxy precursors (Storbeck et al., 2013) and therefore while the kidney inactivates glucocorticoids it may play a vital role in activating 11-oxygenated androgens. Indeed, a recent study showed that while 11OHA4 and 11OHT are of adrenal origin, differences in the concentration of the individual 11-oxygenated steroids in the adrenal vein and inferior vena cava suggest that 11KA4 and 11KT may instead be formed in peripheral tissues (Turcu et al., 2016). The significant levels of 11KA4 measured in the serum of healthy premenopausal woman (O'Reilly et al., 2016) supports the involvement of peripheral tissue such as the kidney, especially considering that the adrenal expresses only low levels of HSD11B2 (Coulter et al., 1999).



## 10.2. Renal excretion and analytical considerations

The main route of androgen excretion is the renal elimination of the conjugated metabolites. Sulfo- and glucoconjugates are excreted in different ratios for every androgen, while the excretion of free forms is negligible (Buiarelli et al., 2004). Renal excretion of conjugates takes advantage of (1) the hydrophilic water-soluble nature of steroid conjugates and (2) the fact that their transport across the cell membrane requires active transport mechanisms which allow for the concentration of the molecules on one side of the membrane (Pritchard and Miller, 1996; VanWert et al., 2010). Organic anion transporters are highly expressed in renal epithelia (Emami Riedmaier et al., 2012). Steroid sulfates are generally excreted at a lower rate than their glucuronidated counterparts as STS catalyse their desulfation. Besides the classical conjugates, T metabolites conjugated with cysteine have been detected in urine and plasma (Fabregat et al., 2013).

As urine collection is non-invasive it is a preferable matrix for steroid analysis. In general, total levels of metabolites (free + conjugated) are measured after de-conjugation by  $\beta$ -glucuronidase treatment. AST and ETIO are measured as representatives of active androgens, while DHEA and 16 $\alpha$ OH-DHEA are measured as representatives of direct androgen precursors (Arlt et al., 2011; Krone et al., 2010). Amounts of excreted androgen and precursor metabolites from typical urinary steroid profiles excreted in a 24 h-period are summarised in Table 3 (Arlt et al., 2011; Kotlowska et al., 2017; Remer et al., 2005). Urinary 11-oxygenated AST and 11-oxygenated ETIO originate from androgen and glucocorticoid metabolism, however in different ratios. While urinary 11-oxygenated ETIO is predominantly a product of glucocorticoid metabolism, urinary 11-oxygenated AST results mainly from 11-oxygenated androgens (Jones et al., 2016; Shackleton et al., 2008). As previously mentioned, 5 $\beta$ -reduction ( $\rightarrow$  ETIO) is indicative of hepatic metabolism (Chen and Penning, 2014), while 5 $\alpha$ -reduction ( $\rightarrow$  AST) takes place in most peripheral tissues (Russell and Wilson, 1994). In the context of intracrinology, 5 $\alpha$ -reduced metabolites are thus of particular interest. The urinary steroid metabolome represents the total of all steroid biosynthetic and metabolising pathways and has proven to be a specific and sensitive biomarker for the diagnosis of steroidogenic disease (Arlt et al., 2011). De-conjugation by  $\beta$ -glucuronidase is time-consuming and may lead to imprecision due to variability in hydrolysis efficiency (Trabert et al., 2016), but to date only a limited number of methods for the simultaneous measurement of free, sulfated and glucuronidated androgens have been established, although significant progress has been made (Badoud et al., 2011; Doue et al., 2015; Galuska et al., 2013). Such approaches also allow the investigation of dysfunction of conjugation pathways in a single run.

As intracrine androgen activation takes place in the cell and may start with the uptake of an androgen precursor and end with the efflux of an inactive androgen metabolite, circulating levels of active androgens are not a valid reflection of total body androgen action (O'Reilly et al., 2014b). The assessment of circulating precursors in particular A4 (Keevil, 2014; O'Reilly et al., 2014b; Pasquali et al., 2016) including 11-oxygenated C<sub>19</sub> steroids (O'Reilly et al., 2016) or androgen metabolites AST-glucuronide, 3 $\alpha$ -adiol-3-glucuronide and 3 $\alpha$ -adiol-17-glucuronide (Labrie et al., 1997a, 1997b; Vandenput et al., 2007) are thus recommended to assess androgen burden.

## 11. Conclusions

Besides its essential function for normal male sexual development (Auchus and Miller, 2012; Krone et al., 2007), androgen intracrinology plays a crucial role for physiology of peripheral

**Table 3**  
**Urinary concentration of C<sub>19</sub> steroid metabolites determined by gas chromatography mass spectrometry after de-conjugation.** All values are shown in  $\mu$ g/24 h. The details of the original studies are given in the footnotes below the table.

Precursor metabolites	Women	Men
DHEA	111 (57–222) <sup>a</sup> 204 (82–378) <sup>c</sup>	396 (179–662) <sup>a</sup> 355 (151–880) <sup>c</sup>
16 $\alpha$ OH-DHEA	278 (188–666) <sup>a</sup>	
7 $\beta$ OH-DHEA	90 (70–100) <sup>b</sup>	
5-androstenediol (5-diol)	78 (47–158) <sup>c</sup>	151 (94–234) <sup>c</sup>
<b>Androgen metabolite</b>		
Androsterone (AST)	936 (733–1442) <sup>a</sup> 1047 <sup>c</sup> 790 (760–830) <sup>b</sup>	2072 (1600–3067) <sup>a</sup> 2138 <sup>c</sup>
Etiocanolone (ETIO)	1321 (837–2041) <sup>a</sup> 955 <sup>c</sup> 920 (880–970) <sup>b</sup>	2066 (1539–2468) 1549 <sup>c</sup>
11 $\beta$ OH-AST*	407 (315–655) <sup>a</sup> 380 (340–440) <sup>b</sup>	1014 (681–1416) <sup>a</sup>
11 $\beta$ OH-ETIO*	236 (110–375) <sup>a</sup> 190 (160–220) <sup>b</sup>	281 (198–498) <sup>a</sup>
11-keto-AST*	160 (120–190) <sup>b</sup>	
11-keto-ETIO*	319 (190–507) <sup>a</sup>	402 (317–644) <sup>a</sup>

\*metabolite of both glucocorticoids and 11-oxygenated androgens to different extents (Shackleton et al., 2008).

<sup>a</sup> Arlt et al. (2011), median (interquartile range), 62 women and 26 men, age 18–60.

<sup>b</sup> Kotlowska et al. (2017), median (interquartile range), combined values for 25 women and 12 men, age >40.

<sup>c</sup> Remer et al. (2005), mean (interquartile range), 25 girls and 25 boys, age 17–18.

tissues in both sexes. Its dysregulation can impair local and systemic metabolic homeostasis and promote sex hormone-dependent cancer, but precise mechanisms remain to be elucidated. Model systems must be carefully chosen and significant differences in adrenal development, C<sub>19</sub> steroidogenesis and subsequent metabolism between humans and common animal models, i.e. rodent and non-human primates, must be taken into account. Because of the major contributions of intracrinology to the androgen levels a peripheral target cell is exposed to, the measurement of androgen precursors (O'Reilly et al., 2014b; Pasquali et al., 2016) and metabolites (Labrie et al., 2006; Vandenput et al., 2007) is recommended to assess local androgen burden and associated health risks. Therefore, more efforts are required to exploit the progress in steroid chromatography/mass spectrometry for comprehensive C<sub>19</sub> steroid profiling and to systematically evaluate such profiles for the establishment of validated links to specific clinical conditions. The tissue-specificity of intracrine pathways in combination with the differential expression of hydroxysteroid dehydrogenases and SRD5A isoforms renders the inhibition of intracrine pathways a promising treatment option in addition to or as a replacement of androgen receptor blockade therapies in sex steroid-dependent cancer. The proof-of-concept has been established by aromatase inhibition in breast cancer and 5 $\alpha$ -reductase inhibition in prostate hyperplasia (Chumsri et al., 2011; Lowe et al., 2003; McConnell et al., 1998). Additionally, androgen biosynthesis from C<sub>21</sub> precursors can be reduced by CYP17A1 inhibition with abiraterone as successfully applied for the treatment of CRPC (Attard et al., 2008; de Bono et al., 2011; James et al., 2017). While androgen metabolism in reproductive tissues is well studied, less is known to date about androgen action in non-classical target tissues, such as the liver and skeletal muscle, which are major compartments responsible for metabolic regulation and metabolic health. Emerging evidence suggests a significant role of androgens in metabolic dysfunction and metabolic disease. Furthermore, the recent discovery of intracrine pathways for the metabolism of 11-oxygenated C<sub>19</sub> steroids requires further investigation at both the

systemic and intracrine levels, especially considering the additional complexity associated with the regulation of these steroids by HSD11B enzymes. Also, the reverse co-regulation of androgen and glucocorticoid action (SRD5A enzymes and HSD11B2 activate androgens, but inactivate glucocorticoids) is a striking phenomenon, which must be unravelled taking tissue-specific conditions into account, as both classes of hormones play key roles in metabolic regulation.

While intracrinology has come a long way since its discovery, much work is still required to understand the cell- and tissue-specific intricacies of its physiological function in both health and disease.

## Acknowledgments

We would like to thank Trish Storbeck for the preparation of the illustrations. This work was funded by the Wellcome Trust (Project Grant 092283, to W.A.), the Academy of Medical Science (Newton Advanced Fellowship, to K-H.S) and the National Research Foundation of South Africa (Grant Number 98886, to K-H.S).

## References

- Abbott, D.H., Bird, I.M., 2009. Nonhuman primates as models for human adrenal androgen production: function and dysfunction. *Rev. Endocr. Metab. Disord.* 10, 33–42.
- Adeniji, A.O., Chen, M., Penning, T.M., 2013. AKR1C3 as a target in castrate resistant prostate cancer. *J. Steroid Biochem. Mol. Biol.* 137, 136–149.
- Africander, D., Storbeck, K.H., 2017 May 17. Steroid metabolism in breast cancer: where are we and what are we missing? *Mol. Cell Endocrinol.* pii: S0303-7207(17)30285-X. [Epub ahead of print].
- Agarwal, A.K., Auchus, R.J., 2005. Minireview: cellular redox state regulates hydroxysteroid dehydrogenase activity and intracellular hormone potency. *Endocrinology* 146, 2531–2538.
- Andersson, S., Berman, D.M., Jenkins, E.P., Russell, D.W., 1991. Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. *Nature* 354, 159–161.
- Andersson, S., Russell, D.W., 1990. Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. *Proc. Natl. Acad. Sci.* 87, 3640–3644.
- Anuka, E., Gal, M., Stocco, D.M., Orly, J., 2013. Expression and roles of steroidogenic acute regulatory (StAR) protein in 'non-classical', extra-adrenal and extra-gonadal cells and tissues. *Mol. Cell Endocrinol.* 371, 47–61.
- Arakawa, H., Nakanishi, T., Yanagihara, C., Nishimoto, T., Wakayama, T., Mizokami, A., Namiki, M., Kawai, K., Tamai, I., 2012. Enhanced expression of organic anion transporting polypeptides (OATPs) in androgen receptor-positive prostate cancer cells: possible role of OATP1A2 in adaptive cell growth under androgen-depleted conditions. *Biochem. Pharmacol.* 84, 1070–1077.
- Arlt, W., Biehl, M., Taylor, A.E., Hahnner, S., Libe, R., Hughes, B.A., Schneider, P., Smith, D.J., Stiekema, H., Krone, N., Porfiri, E., Opocher, G., Bertherat, J., Mantero, F., Allolio, B., Terzolo, M., Nightingale, P., Shackleton, C.H., Bertagna, X., Fassnacht, M., Stewart, P.M., 2011. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. *J. Clin. Endocrinol. Metab.* 96, 3775–3784.
- Arlt, W., Callies, F., van Vlijmen, J.C., Koehler, I., Reincke, M., Bidlingmaier, M., Huebler, D., Oettel, M., Ernst, M., Schulte, H.M., Allolio, B., 1999a. Dehydroepiandrosterone replacement in women with adrenal insufficiency. *N. Engl. J. Med.* 341, 1013–1020.
- Arlt, W., Haas, J., Callies, F., Reincke, M., Hubler, D., Oettel, M., Ernst, M., Schulte, H.M., Allolio, B., 1999b. Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. *J. Clin. Endocrinol. Metab.* 84, 2170–2176.
- Arlt, W., Justl, H.G., Callies, F., Reincke, M., Hubler, D., Oettel, M., Ernst, M., Schulte, H.M., Allolio, B., 1998. Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. *J. Clin. Endocrinol. Metab.* 83, 1928–1934.
- Arlt, W., Martens, J.W.M., Song, M., Wang, J.T., Auchus, R.J., Miller, W.L., 2002. Molecular evolution of adrenarche: structural and functional analysis of P450c17 from four primate species. *Endocrinology* 143, 4665–4672.
- Arlt, W., Walker, E.A., Draper, N., Ivison, H.E., Ride, J.P., Hammer, F., Chalder, S.M., Borucka-Mankiewicz, M., Hauffa, B.P., Malunowicz, E.M., Stewart, P.M., Shackleton, C.H., 2004. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. *Lancet* 363, 2128–2135.
- Attard, G., Reid, A.H., Yap, T.A., Raynaud, F., Dowsett, M., Sattatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., Clark, J., Cooper, C.S., Kaye, S.B., Dearnaley, D., Lee, G., de Bono, J.S., 2008. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. *J. Clin. Oncol.* 26, 4563–4571.
- Auchus, R.J., 2004. The backdoor pathway to dihydrotestosterone. *Trends Endocrinol. Metab.* 15, 432–438.
- Auchus, R.J., Miller, W.L., 2012. Defects in androgen biosynthesis causing 46,XY disorders of sexual development. *Semin. Reprod. Med.* 30, 417–426.
- Auchus, R.J., Rainey, W.E., 2004. Adrenarche – physiology, biochemistry and human disease. *Clin. Endocrinol.* 60, 288–296.
- Avvakumov, G.V., Cherkasov, A., Muller, Y.A., Hammond, G.L., 2010. Structural analyses of sex hormone-binding globulin reveal novel ligands and function. *Mol. Cell. Endocrinol.* 316, 13–23.
- Badoud, F., Grata, E., Boccard, J., Guilleme, D., Veuthey, J.L., Rudaz, S., Saugy, M., 2011. Quantification of glucuronidated and sulfated steroids in human urine by ultra-high pressure liquid chromatography quadrupole time-of-flight mass spectrometry. *Anal. Bioanal. Chem.* 400, 503–516.
- Barbier, O., Belanger, A., 2008. Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate. *Best. Pract. Res. Clin. Endocrinol. Metab.* 22, 259–270.
- Barbieri, R.L., 2014. The endocrinology of the menstrual cycle. *Methods Mol. Biol.* 1154, 145–169.
- Bauman, D.R., Steckelbroeck, S., Williams, M.V., Peehl, D.M., Penning, T.M., 2006. Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease. *Mol. Endocrinol.* 20, 444–458.
- Beattie, M.C., Adekola, L., Papadopoulos, V., Chen, H., Zirkkin, B.R., 2015. Leydig cell aging and hypogonadism. *Exp. Gerontol.* 68, 87–91.
- Belanger, A., Pelletier, G., Labrie, F., Barbier, O., Chouinard, S., 2003. Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. *Trends Endocrinol. Metab.* 14, 473–479.
- Belanger, B., Caron, S., Belanger, A., Dupont, A., 1990. Steroid fatty acid esters in adrenals and plasma: effects of ACTH. *J. Endocrinol.* 127, 505–511.
- Belanger, C., Hould, F.S., Lebel, S., Biron, S., Brochu, G., Tchernof, A., 2006. Omental and subcutaneous adipose tissue steroid levels in obese men. *Steroids* 71, 674–682.
- Bellemare, V., Faucher, F., Breton, R., Luu-The, V., 2005. Characterization of 17alpha-hydroxysteroid dehydrogenase activity (17alpha-HSD) and its involvement in the biosynthesis of epitestosterone. *BMC Biochem.* 6, 12.
- Belyaeva, O.V., Chetyrkin, S.V., Clark, A.L., Kostereva, N.V., SantaCruz, K.S., Chronwall, B.M., Kedishvili, N.Y., 2007. Role of microsomal retinol/sterol dehydrogenase-like short-chain dehydrogenases/reductases in the oxidation and epimerization of 3alpha-hydroxysteroids in human tissues. *Endocrinology* 148, 2148–2156.
- Beusen, D.D., Carrell, H.L., Covey, D.F., 1987. Metabolism of 19-methyl-substituted steroids by human placental aromatase. *Biochemistry* 26, 7833–7841.
- Bird, I.M., 2012. In the zone: understanding zona reticularis function and its transformation by adrenarche. *J. Endocrinol.* 214, 109–111.
- Blanchard, P.G., Luu-The, V., 2007. Differential androgen and estrogen substrates specificity in the mouse and primates type 12 17beta-hydroxysteroid dehydrogenase. *J. Endocrinol.* 194, 449–455.
- Bloem, L.M., Storbeck, K.H., Schloms, L., Swart, A.C., 2013. 11beta-hydroxyandrostenedione returns to the steroid arena: biosynthesis, metabolism and function. *Molecules* 18, 13228–13244.
- Bloem, L.M., Storbeck, K.H., Swart, P., du Toit, T., Schloms, L., Swart, A.C., 2015. Advances in the analytical methodologies: profiling steroids in familial pathways-challenging dogmas. *J. Steroid Biochem. Mol. Biol.* 153, 80–92.
- Blom, T., Ojanotko-Harri, A., Laine, M., Huhtaniemi, I., 1993. Metabolism of progesterone and testosterone in human parotid and submandibular salivary glands in vitro. *J. Steroid Biochem. Mol. Biol.* 44, 69–76.
- Blouin, K., Blanchette, S., Richard, C., Dupont, P., Luu-The, V., Tchernof, A., 2005. Expression and activity of steroid aldoketoreductases 1C in omental adipose tissue are positive correlates of adiposity in women. *Am. J. Physiol. Endocrinol. Metab.* 288, E398–E404.
- Blouin, K., Nadeau, M., Mailloux, J., Daris, M., Lebel, S., Luu-The, V., Tchernof, A., 2009a. Pathways of adipose tissue androgen metabolism in women: depot differences and modulation by adipogenesis. *Am. J. Physiol. Endocrinol. Metab.* 296, E244–E255.
- Blouin, K., Richard, C., Belanger, C., Dupont, P., Daris, M., Laberge, P., Luu-The, V., Tchernof, A., 2003. Local androgen inactivation in abdominal visceral adipose tissue. *J. Clin. Endocrinol. Metab.* 88, 5944–5950.
- Blouin, K., Richard, C., Brochu, G., Hould, F.S., Lebel, S., Marceau, S., Biron, S., Luu-The, V., Tchernof, A., 2006. Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men. *J. Endocrinol.* 191, 637–649.
- Blouin, K., Veilleux, A., Luu-The, V., Tchernof, A., 2009b. Androgen metabolism in adipose tissue: recent advances. *Mol. Cell Endocrinol.* 301, 97–103.
- Boehmer, A.L., Brinkmann, A.O., Sandkuijl, L.A., Halley, D.J., Niermeijer, M.F., Andersson, S., de Jong, F.H., Kayserili, H., de Vroede, M.A., Otten, B.J., Rouwe, C.W., Mendonca, B.B., Rodrigues, C., Bode, H.H., de Ruiter, P.E., Delemarre-van de Waal, H.A., Drop, S.L., 1999. 17Beta-hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations. *J. Clin. Endocrinol. Metab.* 84, 4713–4721.
- Bose, H.S., Whittall, R.M., Huang, M.C., Baldwin, M.A., Miller, W.L., 2000. N-218 MLN64, a protein with StAR-like steroidogenic activity, is folded and cleaved similarly to StAR. *Biochemistry* 39, 11722–11731.



- Buiarelli, F., Coccioli, F., Merolle, M., Neri, B., Terracciano, A., 2004. Development of a liquid chromatography–tandem mass spectrometry method for the identification of natural androgenic steroids and their conjugates in urine samples. *Anal. Chim. Acta* 526, 113–120.
- Bulun, S.E., Simpson, E.R., 1994. Competitive reverse transcription–polymerase chain reaction analysis indicates that levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs, and abdomen of women increase with advancing age. *J. Clin. Endocrinol. Metab.* 78, 428–432.
- Camacho, E.M., Huhtaniemi, I.T., O'Neill, T.W., Finn, J.D., Pye, S.R., Lee, D.M., Tajar, A., Bartfai, G., Boonen, S., Casanueva, F.F., Forti, G., Giwercman, A., Han, T.S., Kula, K., Keevil, B., Lean, M.E., Pendleton, N., Punab, M., Vanderschueren, D., Wu, F.C., 2013. Age-associated changes in hypothalamic–pituitary–testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European male ageing study. *Eur. J. Endocrinol.* 168, 445–455.
- Cantagrel, V., Lefeber, D.J., Ng, B.G., Guan, Z., Silhavy, J.L., Bielas, S.L., Lehle, L., Hombauer, H., Adamowicz, M., Swiezewska, E., De Brouwer, A.P., Blumel, P., Sykut-Cegielska, J., Houliston, S., Swistun, D., Ali, B.R., Dobyns, W.B., Babovic-Vuksanovic, D., van Bokhoven, H.F., Wevers, R.A., Raetz, C.R., Freeze, H.H., Morava, E., Al-Gazali, L., Gleeson, J.G., 2010. SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. *Cell* 142, 203–217.
- Capper, C.P., Rae, J.M., Auchus, R.J., 2016. The metabolism, analysis, and targeting of steroid hormones in breast and prostate cancer. *Hormones Cancer* 7, 149–164.
- Chang, K.H., Li, R., Papari-Zareei, M., Watumull, L., Zhao, Y.D., Auchus, R.J., Sharifi, N., 2011. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. *Proc. Natl. Acad. Sci. U. S. A.* 108, 13728–13733.
- Charbonneau, A., The, V.L., 2001. Genomic organization of a human 5 $\beta$ -reductase and its pseudogene and substrate selectivity of the expressed enzyme. *Biochim. Biophys. Acta* 1517, 228–235.
- Chen, M., Drury, J.E., Penning, T.M., 2011. Substrate specificity and inhibitor analyses of human steroid 5 $\beta$ -reductase (AKR1D1). *Steroids* 76, 484–490.
- Chen, M., Penning, T.M., 2014. 5 $\beta$ -Reduced steroids and human Delta(4)-3-ketosteroid 5 $\beta$ -reductase (AKR1D1). *Steroids* 83, 17–26.
- Chen, W., Tsai, S.J., Sheu, H.M., Tsai, J.C., Zouboulis, C.C., 2010. Testosterone synthesized in cultured human SZ95 sebocytes derives mainly from dehydroepiandrosterone. *Exp. Dermatol.* 19, 470–472.
- Cherkasov, A., Ban, F., Santos-Filho, O., Thorsteinson, N., Fallahi, M., Hammond, G.L., 2008. An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin. *J. Med. Chem.* 51, 2047–2056.
- Chouinard, S., Barbier, O., Belanger, A., 2007. UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells. *J. Biol. Chem.* 282, 33466–33474.
- Chumsri, S., Howes, T., Bao, T., Sabnis, G., Brodie, A., 2011. Aromatase, aromatase inhibitors, and breast cancer. *J. Steroid Biochem. Mol. Biol.* 125, 13–22.
- Cloutier, M., Fleury, A., Courtemanche, J., Ducharme, L., Mason, J.L., Lehoux, J.G., 1995. Cloning and expression of hamster adrenal cytochrome P450C17 cDNA. *Ann. N. Y. Acad. Sci.* 774, 294–296.
- Cloutier, M., Fleury, A., Courtemanche, J., Ducharme, L., Mason, J.L., Lehoux, J.G., 1997. Characterization of the adrenal cytochrome P450C17 in the hamster, a small animal model for the study of adrenal dehydroepiandrosterone biosynthesis. *DNA Cell Biol.* 16, 357–368.
- Cohen, P.G., 1999. The hypogonadal–obesity cycle: role of aromatase in modulating the testosterone–estradiol shunt – a major factor in the genesis of morbid obesity. *Med. Hypotheses* 52, 49–51.
- Conte, F.A., Grumbach, M.M., Ito, Y., Fisher, C.R., Simpson, E.R., 1994. A syndrome of female pseudohermaphroditism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). *J. Clin. Endocrinol. Metab.* 78, 1287–1292.
- Conway, G., Dewailly, D., Diamanti-Kandaraki, E., Escobar-Morreale, H.F., Franks, S., Gambineri, A., Kelestimur, E., Macut, D., Micic, D., Pasquali, R., Pfeifer, M., Pignatelli, D., Pugeat, M., Yildiz, B.O., 2014. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. *Eur. J. Endocrinol.* 171, P1–P29.
- Cook, I.T., Duniec-Dmuchowski, Z., Kocarek, T.A., Runge-Morris, M., Falany, C.N., 2009. 24-hydroxycholesterol sulfation by human cytosolic sulfotransferases: formation of monosulfates and disulfates, molecular modeling, sulfatase sensitivity, and inhibition of liver x receptor activation. *Drug Metab. Dispos.* 37, 2069–2078.
- Coulter, C.L., Smith, R.E., Stowasser, M., Sasano, H., Krozowski, Z.S., Gordon, R.D., 1999. Expression of 11 $\beta$ -hydroxysteroid dehydrogenase type 2 (11 $\beta$ HSD-2) in the developing human adrenal gland and human adrenal cortical carcinoma and adenoma. *Mol. Cell Endocrinol.* 154, 71–77.
- Couzinet, B., Meduri, G., Lecce, M.G., Young, J., Brailly, S., Loosfelt, H., Milgrom, E., Schaison, G., 2001. The postmenopausal ovary is not a major androgen-producing gland. *J. Clin. Endocrinol. Metab.* 86, 5060–5066.
- Covey, D.F., Carrell, H.L., Beusen, D.D., 1987. Metabolism of 19-methyl substituted steroids and a proposal for the third aromatase monooxygenation. *Steroids* 50, 363–374.
- Damgaard-Olesen, A., Johannsen, T.H., Holmboe, S.A., Søbørg, T., Petersen, J.H., Andersson, A.M., Aadahl, M., Linneberg, A., Juul, A., 2016. Reference ranges of 17-hydroxyprogesterone, DHEA, DHEAS, androstenedione, total and free testosterone determined by TurboFlow-LC–MS/MS and associations to health markers in 304 men. *Clin. Chim. Acta* 454, 82–88.
- de Bono, J.S., Logothetis, C.J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K.N., Jones, R.J., Goodman Jr., O.B., Saad, F., Staffurth, J.N., Mainwaring, P., Harland, S., Flaig, T.W., Hutson, T.E., Cheng, T., Patterson, H., Hainsworth, J.D., Ryan, C.J., Sternberg, C.N., Ellard, S.L., Flechon, A., Saleh, M., Scholz, M., Efstathiou, E., Zivi, A., Bianchini, D., Loriot, Y., Chieffo, N., Kheoh, T., Haqq, C.M., Scher, H.L., 2011. Abiraterone and increased survival in metastatic prostate cancer. *N. Engl. J. Med.* 364, 1995–2005.
- de Launoit, Y., Simard, J., Durocher, F., Labrie, F., 1992. Androgenic 17  $\beta$ -hydroxysteroid dehydrogenase activity of expressed rat type 1 3  $\beta$ -hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase. *Endocrinology* 130, 553–555.
- Deeley, R.G., Westlake, C., Cole, S.P., 2006. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. *Physiol. Rev.* 86, 849–899.
- Dehennin, L., Bonnaire, Y., Plou, P., 1999. Urinary excretion of 19-norandrosterone of endogenous origin in man: quantitative analysis by gas chromatography–mass spectrometry. *J. Chromatogr. B Biomed. Sci. Appl.* 721, 301–307.
- Diamond, P., Cusan, L., Gomez, J.-L., Bélanger, A., Labrie, F., 1996. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. *J. Endocrinol.* 150, S43–S50.
- Djoseland, O., de Besche, A., Hoglo, S., Rennie, P.S., 1982. Steroid metabolism by normal and neoplastic parotid tissue. *J. Steroid Biochem.* 16, 397–402.
- Doue, M., Dervilly-Pinel, G., Pouponneau, K., Monteau, F., Le Bizet, B., 2015. Analysis of glucuronide and sulfate steroids in urine by ultra-high-performance supercritical-fluid chromatography hyphenated tandem mass spectrometry. *Anal. Bioanal. Chem.* 407, 4473–4484.
- du Toit, T., Bloem, L.M., Quanson, J.L., Ehlers, R., Serafin, A.M., Swart, A.C., 2017. Profiling adrenal 11 $\beta$ -hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC2-MS/MS quantification of 11 $\beta$ -hydroxytestosterone, 11keto-testosterone and 11keto-dihydrotestosterone. *J. Steroid Biochem. Mol. Biol.* 166, 54–67.
- Dunn, J.F., Nisula, B.C., Rodbard, D., 1981. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. *J. Clin. Endocrinol. Metab.* 53, 58–68.
- Edwards, C.R., Stewart, P.M., 1991. The cortisol–cortisone shuttle and the apparent specificity of glucocorticoid and mineralocorticoid receptors. *J. Steroid Biochem. Mol. Biol.* 39, 859–865.
- El Kihel, L., 2012. Oxidative metabolism of dehydroepiandrosterone (DHEA) and biologically active oxygenated metabolites of DHEA and epiandrosterone (EpiA)—recent reports. *Steroids* 77, 10–26.
- Emami Riedmaier, A., Nies, A.T., Schaeffeler, E., Schwab, M., 2012. Organic anion transporters and their implications in pharmacotherapy. *Pharmacol. Rev.* 64, 421–449.
- Escobar, J.C., Patel, S.S., Beshay, V.E., Suzuki, T., Carr, B.R., 2011. The human placenta expresses CYP17 and generates androgens de novo. *J. Clin. Endocrinol. Metab.* 96, 1385–1392.
- Fabregat, A., Kotronoulas, A., Marcos, J., Joglar, J., Alfonso, I., Segura, J., Ventura, R., Pozo, O.J., 2013. Detection, synthesis and characterization of metabolites of steroid hormones conjugated with cysteine. *Steroids* 78, 327–336.
- Falany, C.N., He, D., Dumas, N., Frost, A.R., Falany, J.L., 2006. Human cytosolic sulfotransferase 2B1: isoform expression, tissue specificity and subcellular localization. *J. Steroid Biochem. Mol. Biol.* 102, 214–221.
- Falany, J.L., Maccrina, N., Falany, C.N., 2004. Sulfation of tibolone and tibolone metabolites by expressed human cytosolic sulfotransferases. *J. Steroid Biochem. Mol. Biol.* 88, 383–391.
- Fassnacht, M., Schlenz, N., Schneider, S.B., Wudy, S.A., Allolio, B., Arlt, W., 2003. Beyond adrenal and ovarian androgen generation: increased peripheral 5  $\alpha$ -reductase activity in women with polycystic ovary syndrome. *J. Clin. Endocrinol. Metab.* 88, 2760–2766.
- Fluck, C.E., Miller, W.L., Auchus, R.J., 2003. The 17, 20-lyase activity of cytochrome p450c17 from human fetal testis favors the delta5 steroidogenic pathway. *J. Clin. Endocrinol. Metab.* 88, 3762–3766.
- Fogle, R.H., Stanczyk, F.Z., Zhang, X., Paulson, R.J., 2007. Ovarian androgen production in postmenopausal women. *J. Clin. Endocrinol. Metab.* 92, 3040–3043.
- Fritsch, M., Orfanos, C.E., Zouboulis, C.C., 2001. Sebocytes are the key regulators of androgen homeostasis in human skin. *J. Invest. Dermatol.* 116, 793–800.
- Fujimura, T., Takahashi, S., Urano, T., Kumagai, J., Murata, T., Takayama, K., Ogushi, T., Horie-Inoue, K., Ouchi, Y., Kitamura, T., Muramatsu, M., Homma, Y., Inoue, S., 2009. Expression of cytochrome P450 3A4 and its clinical significance in human prostate cancer. *Urology* 74, 391–397.
- Funder, J.W., Pearce, P.T., Smith, R., Smith, A.I., 1988. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. *Science* 242, 583–585.
- Fung, K.M., Samara, E.N., Wong, C., Metwalli, A., Krlin, R., Bane, B., Liu, C.Z., Yang, J.T., Pitha, J.V., Cullkin, D.J., Kropp, B.P., Penning, T.M., Lin, H.K., 2006. Increased expression of type 2 3 $\alpha$ -hydroxysteroid dehydrogenase/type 5 17 $\beta$ -hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. *Endocr. Relat. Cancer* 13, 169–180.
- Galuska, C.E., Hartmann, M.F., Sanchez-Guijo, A., Bakhaus, K., Geyer, J., Schuler, G., Zimmer, K.P., Wudy, S.A., 2013. Profiling intact steroid sulfates and unconjugated steroids in biological fluids by liquid chromatography–tandem mass spectrometry (LC–MS–MS). *Analyst* 138, 3792–3801.
- Gathercole, L.L., Lavery, G.G., Morgan, S.A., Cooper, M.S., Sinclair, A.J., Tomlinson, J.W., Stewart, P.M., 2013. 11 $\beta$ -Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects. *Endocr. Rev.* 34, 525–555.

- Gauthier-Landry, L., Belanger, A., Barbier, O., 2015. Multiple roles for UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution. *J. Steroid Biochem. Mol. Biol.* 145, 187–192.
- Geisler, J., Sasano, H., Chen, S., Purohit, A., 2011. Steroid sulfatase inhibitors: promising new tools for breast cancer therapy? *J. Steroid Biochem. Mol. Biol.* 125, 39–45.
- Gell, J.S., Atkins, B., Margraf, L., Mason, J.I., Sasano, H., Rainey, W.E., Carr, B.R., 1996. Adrenarche is associated with decreased 3 beta-hydroxysteroid dehydrogenase expression in the adrenal reticularis. *Endocr. Res.* 22, 723–728.
- Ghosh, D., 2007. Human sulfatases: a structural perspective to catalysis. *Cell Mol. Life Sci.* 64, 2013–2022.
- Gibson, D.A., McInnes, K.J., Critchley, H.O., Saunders, P.T., 2013. Endometrial Intracrine—generation of an estrogen-dominated microenvironment in the secretory phase of women. *J. Clin. Endocrinol. Metab.* 98, E1802–E1806.
- Gibson, D.A., Simitidellis, I., Cousins, F.L., Critchley, H.O., Saunders, P.T., 2016. Intracrine androgens enhance decidualization and modulate expression of human endometrial receptivity genes. *Sci. Rep.* 6, 19970.
- Gilligan, L.C., Gondal, A., Tang, V., Hussain, M.T., Arvaniti, A., Hewitt, A.M., Foster, P.A., 2017. Estrone sulfate transport and steroid sulfatase activity in colorectal cancer: implications for hormone replacement therapy. *Front. Pharmacol.* 8, 103.
- Giorgi, E.P., Stein, W.D., 1981. The transport of steroids into animal cells in culture. *Endocrinology* 108, 688–697.
- Golan, R., Scovell, J.M., Ramasamy, R., 2015. Age-related testosterone decline is due to waning of both testicular and hypothalamic-pituitary function. *Aging Male* 18, 201–204.
- Gonzales, E., Cresteil, D., Baussan, C., Dabadie, A., Gerhardt, M.-F., Jacquemin, E., 2004. SRD5B1 (AKR1D1) gene analysis in  $\Delta 4$ -3-oxosteroid 5 $\beta$ -reductase deficiency: evidence for primary genetic defect. *J. Hepatol.* 40, 716–718.
- Grant, D.J., Hoy, C., Oliver, S.D., Gerber, L., Shuler, K., Calloway, E., Gaines, A.R., McPhail, M., Livingston, J.N., Richardson, R.M., Schildkraut, J.M., Freedland, S.J., 2013. Association of uridine diphosphate-glucuronosyltransferase 2B gene variants with serum glucuronide levels and prostate cancer risk. *Genet. Test. Mol. Biomarkers* 17, 3–9.
- Grishkovskaya, I., Avvakumov, G.V., Hammond, G.L., Catalano, M.G., Muller, Y.A., 2002. Steroid ligands bind human sex hormone-binding globulin in specific orientations and produce distinct changes in protein conformation. *J. Biol. Chem.* 277, 32086–32093.
- Gupta, M.K., Guryev, O.L., Auchus, R.J., 2003. 5 $\alpha$ -reduced C21 steroids are substrates for human cytochrome P450c17. *Archives Biochem. Biophys.* 418, 151–160.
- Hammer, F., Subtil, S., Lux, P., Maser-Gluth, C., Stewart, P.M., Alolio, B., Arlt, W., 2005. No evidence for hepatic conversion of dehydroepiandrosterone (DHEA) sulfate to DHEA: in vivo and in vitro studies. *J. Clin. Endocrinol. Metab.* 90, 3600–3605.
- Hammond, G.L., 2016. Plasma steroid-binding proteins: primary gatekeepers of steroid hormone action. *J. Endocrinol.* 230, R13–R25.
- Hammond, G.L., Ruokonen, A., Konturi, M., Koskela, E., Vihko, R., 1977. The simultaneous radioimmunoassay of seven steroids in human spermatic and peripheral venous blood. *J. Clin. Endocrinol. Metab.* 45, 16–24.
- Hanig, J.R., Austin, C.W., Carlson, I.H., Kuzma, D.L., Zweibel, W.J., 1985. Role of dehydroepiandrosterone sulfate as a prehormone for ovarian steroidogenesis. *Obstet. Gynecol.* 65, 199–205.
- Harada, N., 1988. Novel properties of human placental aromatase as cytochrome P-450: purification and characterization of a unique form of aromatase. *J. Biochem.* 103, 106–113.
- Haring, R., Hannemann, A., John, U., Radke, D., Nauck, M., Wallaschofski, H., Owen, L., Adaway, J., Keevil, B.G., Brabant, G., 2012. Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry. *J. Clin. Endocrinol. Metab.* 97, 408–415.
- Havlikova, H., Hill, M., Hamp, R., Starka, L., 2002. Sex- and age-related changes in epitestosterone in relation to pregnenolone sulfate and testosterone in normal subjects. *J. Clin. Endocrinol. Metab.* 87, 2225–2231.
- Hawley, J.M., Keevil, B.G., 2016. Endogenous glucocorticoid analysis by liquid chromatography–tandem mass spectrometry in routine clinical laboratories. *J. Steroid Biochem. Mol. Biol.* 162, 27–40.
- He, D., Frost, A.R., Falany, C.N., 2005. Identification and immunohistochemical localization of Sulfotransferase 2B1b (SULT2B1b) in human lung. *Biochim. Biophys. Acta (BBA) - General Subj.* 1724, 119–126.
- Hennebert, O., Chabot, S., Alran, S., Morfin, R., 2007. Dehydroepiandrosterone 7 $\alpha$ -hydroxylation in human tissues: possible interference with type 1 11 $\beta$ -hydroxysteroid dehydrogenase-mediated processes. *J. Steroid Biochem. Mol. Biol.* 104, 326–333.
- Herbison, A.E., 2016. Control of puberty onset and fertility by gonadotropin-releasing hormone neurons. *Nat. Rev. Endocrinol.* 12, 452–466.
- Hickey, T.E., Robinson, J.L., Carroll, J.S., Tilley, W.D., 2012. Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? *Mol. Endocrinol.* 26, 1252–1267.
- Hillier, S.G., Whitelaw, P.F., Smyth, C.D., 1994. Follicular oestrogen synthesis: the 'two-cell, two-gonadotrophin' model revisited. *Mol. Cell Endocrinol.* 100, 51–54.
- Hirasawa, G., Sasano, H., Takahashi, K.-i., Fukushima, K., Suzuki, T., Hiwatashi, N., Toyota, T., Krozowski, Z.S., Nagura, H., 1997. Colocalization of 11 $\beta$ -hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human epithelia. *J. Clin. Endocrinol. Metab.* 82, 3859–3863.
- Hobkirk, R., 1993. Steroid sulfation Current concepts. *Trends Endocrinol. Metab.* 4, 69–74.
- Hochberg, R.B., 1998. Biological esterification of steroids. *Endocr. Rev.* 19, 331–348.
- Hofland, J., van Weerden, W.M., Dits, N.F., Steenbergen, J., van Leenders, G.J., Jenster, G., Schroder, F.H., de Jong, F.H., 2010. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. *Cancer Res.* 70, 1256–1264.
- Hogveen, K.N., Cousin, P., Pugeat, M., Dewailly, D., Soudan, B., Hammond, G.L., 2002. Human sex hormone-binding globulin variants associated with hyperandrogenism and ovarian dysfunction. *J. Clin. Invest.* 109, 973–981.
- Homma, K., Hasegawa, T., Nagai, T., Adachi, M., Horikawa, R., Fujiwara, I., Tajima, T., Takeda, R., Fukami, M., Ogata, T., 2006. Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone. *J. Clin. Endocrinol. Metab.* 91, 2643–2649.
- Idkowiak, J., Lavery, G.G., Dhir, V., Barrett, T.G., Stewart, P.M., Krone, N., Arlt, W., 2011. Premature adrenarche: novel lessons from early onset androgen excess. *Eur. J. Endocrinol.* 165, 189–207.
- Idkowiak, J., Taylor, A.E., Subtil, S., O'Neil, D.M., Vijzelaar, R., Dias, R.P., Amin, R., Barrett, T.G., Shackleton, C.H., Kirk, J.M., Moss, C., Arlt, W., 2016. Steroid sulfatase deficiency and androgen activation before and after puberty. *J. Clin. Endocrinol. Metab.* 101, 2545–2553.
- Imperato-McGinley, J., Guerrero, L., Gautier, T., Peterson, R.E., 1974. Steroid 5 $\alpha$ -reductase deficiency in man: an inherited form of male pseudohermaphroditism. *Science* 186, 1213–1215.
- Ishida, H., Tashiro, H., Watanabe, M., Fujii, N., Imamura, K., Minowada, S., Shinohara, M., Fukutani, K., Aso, Y., De Kretser, D.M., 1990. Measurement of inhibin concentrations in men: study of changes after castration and comparison with androgen levels in testicular tissue, spermatic venous blood, and peripheral venous blood. *J. Clin. Endocrinol. Metab.* 70, 1019–1022.
- Jakobsson, J., Ekstrom, L., Inotsume, N., Garle, M., Lorentzon, M., Ohlsson, C., Roh, H.K., Carlstrom, K., Rane, A., 2006. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. *J. Clin. Endocrinol. Metab.* 91, 687–693.
- James, N.D., de Bono, J.S., Spears, M.R., Clarke, N.W., Mason, M.D., Dearnaley, D.P., Ritchie, A.W.S., Amos, C.L., Gilson, C., Jones, R.J., Matheson, D., Millman, R., Attard, C., Chowdhury, S., Cross, W.R., Gillesen, S., Parker, C.C., Russell, J.M., Berthold, D.R., Brawley, C., Adab, F., Aung, S., Birtle, A.J., Bowen, J., Brock, S., Chakraborti, P., Ferguson, C., Gale, J., Gray, E., Hingorani, M., Hoskin, P.J., Lester, J.F., Malik, Z.I., McKinna, F., McPhail, N., Money-Kyrle, J., O'Sullivan, J., Parikh, O., Protheroe, A., Robinson, A., Srihari, N.N., Thomas, C., Wagstaff, J., Wylie, J., Zarkar, A., Parmar, M.K.B., Sydes, M.R., 2017 Jul 27. Abiraterone for prostate cancer not previously treated with hormone therapy. *N. Engl. J. Med.* 377 (4), 338–351.
- Jin, Y., Duan, L., Lee, S.H., Kloosterboer, H.J., Blair, I.A., Penning, T.M., 2009. Human cytosolic hydroxysteroid dehydrogenases of the aldo-ketoreductase superfamily catalyze reduction of conjugated steroids: implications for phase I and phase II steroid hormone metabolism. *J. Biol. Chem.* 284, 10013–10022.
- Jin, Y., Mesaros, A.C., Blair, I.A., Penning, T.M., 2011. Stereospecific reduction of 5 $\beta$ -reduced steroids by human ketosteroid reductases of the AKR (aldo-keto reductase) superfamily: role of AKR1C1-AKR1C4 in the metabolism of testosterone and progesterone via the 5 $\beta$ -reductase pathway. *Biochem. J.* 437, 53–61.
- Jones, C.M., Mallappa, A., Reisch, N., Nikolaou, N., Krone, N., Hughes, B.A., O'Neil, D.M., Whitaker, M.J., Tomlinson, J.W., Storbeck, K.H., Merke, D.P., Ross, R.J., Arlt, W., 2016. Modified release and conventional glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia. *J. Clin. Endocrinol. Metab.* jc20162855.
- Jones, D.L., James, V.H., 1985. The identification, quantification and possible origin of non-polar conjugates in human plasma. *J. Steroid Biochem.* 22, 243–247.
- Ju, R., Wu, W., Fei, J., Qin, Y., Tang, Q., Wu, D., Xia, Y., Wu, J., Wang, X., 2015. Association analysis between the polymorphisms of HSD17B5 and HSD17B6 and risk of polycystic ovary syndrome in Chinese population. *Eur. J. Endocrinol.* 172, 227–233.
- Kalogera, E., Pistos, C., Provatoopoulou, X., Athanaselis, S., Spiliopoulou, C., Gounaris, A., 2013. Androgen glucuronides analysis by liquid chromatography tandem-mass spectrometry: could it raise new perspectives in the diagnostic field of hormone-dependent malignancies? *J. Chromatogr. B* 940, 24–34.
- Kalra, M., Mayes, J., Assefa, S., Kaul, A.K., Kaul, R., 2008. Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. *World J. Gastroenterol.* 14, 5945–5961.
- Kamrath, C., Hochberg, Z., Hartmann, M.F., Remer, T., Wudy, S.A., 2012. Increased activation of the alternative "backdoor" pathway in patients with 21-hydroxylase deficiency: evidence from urinary steroid hormone analysis. *J. Clin. Endocrinol. Metab.* 97, E367–E375.
- Kanda, N., Watanabe, S., 2004a. 17 $\beta$ -estradiol enhances the production of granulocyte-macrophage colony-stimulating factor in human keratinocytes. *J. Invest. Dermatol.* 123, 329–337.
- Kanda, N., Watanabe, S., 2004b. 17 $\beta$ -estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression. *J. Invest. Dermatol.* 123, 319–328.
- Kanda, T., Jiang, X., Yokosuka, O., 2014. Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers. *World J. Gastroenterol.* 20, 9229–9236.
- Kaufman, K.D., Dawber, R.P., 1999. Finasteride, a Type 2 5 $\alpha$ -reductase inhibitor, in the treatment of men with androgenetic alopecia. *Expert Opin. Investig.*

- Drugs 8, 403–415.
- Ke, Y., Gonthier, R., Simard, J.N., Labrie, F., 2016 Apr. A validated LC-MS/MS method for the sensitive quantitation of serum 7alpha hydroxy-, 7beta hydroxy- and 7keto-dehydroepiandrosterone using a novel derivatization reagent. *Steroids* 108, 112–117. <http://dx.doi.org/10.1016/j.steroids.2016.02.005>. Epub 2016 Feb 11. PMID: 26855361.
- Keevil, B.G., 2014. How do we measure hyperandrogenemia in patients with PCOS? *J. Clin. Endocrinol. Metab.* 99, 777–779.
- Keevil, B.G., 2016. LC-MS/MS analysis of steroids in the clinical laboratory. *Clin. Biochem.* 49, 989–997.
- Kelly, D.M., Jones, T.H., 2015. Testosterone and obesity. *Obes. Rev.* 16, 581–606.
- Kondo, K.H., Kai, M.H., Setoguchi, Y., Eggertsen, G., Sjoblom, P., Setoguchi, T., Okuda, K.I., Bjorkhem, I., 1994. Cloning and expression of cDNA of human delta 4-3-oxosteroid 5 beta-reductase and substrate specificity of the expressed enzyme. *Eur. J. Biochem.* 219, 357–363.
- Konttinen, Y.T., Stegajev, V., Al-Samadi, A., Porola, P., Hietanen, J., Ainola, M., 2015. Sjogren's syndrome and extragonadal sex steroid formation: a clue to a better disease control? *J. Steroid Biochem. Mol. Biol.* 145, 237–244.
- Kotlowska, A., Puzyn, T., Sworczak, K., Stepnowski, P., Szefer, P., 2017. Metabolomic biomarkers in urine of Cushing's syndrome patients. *Int. J. Mol. Sci.* 18.
- Krone, N., Hanley, N.A., Arlt, W., 2007. Age-specific changes in sex steroid biosynthesis and sex development. *Best. Pract. Res. Clin. Endocrinol. Metab.* 21, 393–401.
- Krone, N., Hughes, B.A., Lavery, G.G., Stewart, P.M., Arlt, W., Shackleton, C.H., 2010. Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS). *J. Steroid Biochem. Mol. Biol.* 121, 496–504.
- Krone, N., Reisch, N., Idkowiak, J., Dhir, V., Ivison, H.E., Hughes, B.A., Rose, I.T., O'Neil, D.M., Vijzelaar, R., Smith, M.J., MacDonald, F., Cole, T.R., Adolphs, N., Barton, J.S., Blair, E.M., Braddock, S.R., Collins, F., Cragun, D.L., Dattani, M.T., Day, R., Dougan, S., Feist, M., Gottschalk, M.E., Gregory, J.W., Haim, M., Harrison, R., Olney, A.H., Hauffa, B.P., Hindmarsh, P.C., Hopkin, R.J., Jira, P.E., Kempers, M., Kerstens, M.N., Khalifa, M.M., Kohler, B., Maiter, D., Nielsen, S., O'Riordan, S.M., Roth, C.L., Shane, K.P., Silink, M., Stikkelbroeck, N.M., Sweeney, E., Szarras-Czapnik, M., Waterson, J.R., Williamson, L., Hartmann, M.F., Taylor, N.F., Wudy, S.A., Malunowicz, E.M., Shackleton, C.H., Arlt, W., 2012. Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. *J. Clin. Endocrinol. Metab.* 97, E257–E267.
- Labrie, C., Belanger, A., Labrie, F., 1988. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. *Endocrinology* 123, 1412–1417.
- Labrie, F., 1991. Intracrinology. *Mol. Cell Endocrinol.* 78, C113–C118.
- Labrie, F., 2015. All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause. *J. Steroid Biochem. Mol. Biol.* 145, 133–138.
- Labrie, F., Belanger, A., Belanger, P., Berube, R., Martel, C., Cusan, L., Gomez, J., Candas, B., Castiel, I., Chaussade, V., Deloche, C., Leclaire, J., 2006. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. *J. Steroid Biochem. Mol. Biol.* 99, 182–188.
- Labrie, F., Bélanger, A., Bélanger, P., Bérubé, R., Martel, C., Cusan, L., Gomez, J., Candas, B., Chaussade, V., Castiel, I., Deloche, C., Leclaire, J., 2007. Metabolism of DHEA in postmenopausal women following percutaneous administration. *J. Steroid Biochem. Mol. Biol.* 103, 178–188.
- Labrie, F., Belanger, A., Cusan, L., Candas, B., 1997a. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. *J. Clin. Endocrinol. Metab.* 82, 2403–2409.
- Labrie, F., Bélanger, A., Cusan, L., Gomez, J.-L., Candas, B., 1997b. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. *J. Clin. Endocrinol. Metab.* 82, 2396–2402.
- Labrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., Pelletier, G., 2003. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. *Endocr. Rev.* 24, 152–182.
- Labrie, F., Luu-The, V., Labrie, C., Pelletier, G., El-Alfy, M., 2000. Intracrinology and the skin. *Horm. Res.* 54, 218–229.
- Labrie, F., Luu-The, V., Labrie, C., Simard, J., 2001. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. *Front. Neuroendocrinol.* 22, 185–212.
- Labrie, F., Martel, C., Balser, J., 2011. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? *Menopause* 18, 30–43.
- Labrie, F., Martel, C., Belanger, A., Pelletier, G., 2017 Apr. Androgens in women are essentially made from DHEA in each peripheral tissue according to intracrinology. *J. Steroid Biochem. Mol. Biol.* 168, 9–18.
- Labrie, F., Simard, J., Luu-The, V., Belanger, A., Pelletier, G., 1992. Structure, function and tissue-specific gene expression of 3beta-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues. *J. Steroid Biochem. Mol. Biol.* 43, 805–826.
- Larionov, A.A., Vasylyev, D.A., Mason, J.L., Howie, A.F., Berstein, L.M., Miller, W.R., 2003. Aromatase in skeletal muscle. *J. Steroid Biochem. Mol. Biol.* 84, 485–492.
- Laurent, M.R., Helsen, C., Antonio, L., Schollaert, D., Joniau, S., Vos, M.J., Decallonne, B., Hammond, G.L., Vanderschueren, D., Claessens, F., 2016. Effects of sex hormone-binding globulin (SHBG) on androgen bioactivity in vitro. *Mol. Cell Endocrinol.* 437, 280–291.
- Lavallee, B., Provost, P.R., Roy, R., Gauthier, M.C., Belanger, A., 1996. Dehydroepiandrosterone-fatty acid esters in human plasma: formation, transport and delivery to steroid target tissues. *J. Endocrinol.* 150 (Suppl. 1), S119–S124.
- Le Goascogne, C., Sananes, N., Guezou, M., Takemori, S., Kominami, S., Baulieu, E.E., Robel, P., 1991. Immunoreactive cytochrome P-450(17 alpha) in rat and Guinea-pig gonads, adrenal glands and brain. *J. Reprod. Fertil.* 93, 609–622.
- Lebbe, M., Taylor, A.E., Visser, J.A., Kirkman-Brown, J., Woodruff, T.K., Arlt, W., 2017 Feb 23. The steroid metabolome in the isolated ovarian follicle and its response to androgen exposure and antagonism. *Endocrinology*. <http://dx.doi.org/10.1210/en.2016-1851> [Epub ahead of print].
- Lee, M.J., Cha, H.J., Lim, K.M., Lee, O.K., Bae, S., Kim, C.H., Lee, K.H., Lee, Y.N., Ahn, K.J., An, S., 2015. Analysis of the microRNA expression profile of normal human dermal papilla cells treated with 5alpha-dihydrotestosterone. *Mol. Med. Rep.* 12, 1205–1212.
- Lemondé, H.A., Custard, E.J., Bouquet, J., Duran, M., Overmars, H., Scambler, P.J., Clayton, P.T., 2003. Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid 5beta-reductase, in hepatitis and liver failure in infancy. *Curr. Biol.* 13, 1494–1499.
- Lin, H.-K., Jez, J.M., Schlegel, B.P., Peehl, D.M., Pachter, J.A., Penning, T.M., 1997. Expression and characterization of recombinant type 2 3alpha-Hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3alpha/17beta-HSD activity and cellular distribution. *Mol. Endocrinol.* 11, 171–184.
- Longcope, C., Fineberg, S.E., 1985. Production and metabolism of dihydrotestosterone in peripheral tissues. *J. Steroid Biochem.* 23, 415–419.
- Longcope, C., Pratt, J.H., Stephen, H.S., Fineberg, S.E., 1978. Aromatization of androgens by muscle and adipose tissue in vivo. *J. Clin. Endocrinol. Metab.* 46, 146–152.
- Lowe, F.C., McConnell, J.D., Hudson, P.B., Romas, N.A., Boake, R., Lieber, M., Elhilali, M., Geller, J., Imperto-McGinley, J., Andriole, G.L., Bruskewitz, R.C., Walsh, P.C., Bartsch, G., Nacey, J.N., Shah, S., Pappas, F., Ko, A., Cook, T., Stoner, E., Waldstreicher, J., 2003. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. *Urology* 61, 791–796.
- Luu-The, V., Bélanger, A., Labrie, F., 2008. Androgen biosynthetic pathways in the human prostate. *Best Pract. Res. Clin. Endocrinol. Metab.* 22, 207–221.
- Luu-The, V., Labrie, F., 2010. The intracrine sex steroid biosynthesis pathways. *Prog. Brain Res.* 181, 177–192.
- Luu-The, V., Sugimoto, Y., Puy, L., Labrie, Y., Lopez Solache, I., Singh, M., Labrie, F., 1994. Characterization, expression, and immunohistochemical localization of 5 alpha-reductase in human skin. *J. Invest. Dermatol.* 102, 221–226.
- Luu-The, V.A.N., Dufort, I., Paquet, N., Reimnitz, G.U.Y., Labrie, F., 1995. Structural characterization and expression of the human dehydroepiandrosterone sulfotransferase gene. *DNA Cell Biol.* 14, 511–518.
- MacKrell, J.G., Yaden, B.C., Bullock, H., Chen, K., Shetler, P., Bryant, H.U., Krishnan, V., 2015. Molecular targets of androgen signaling that characterize skeletal muscle recovery and regeneration. *Nucl. Recept Signal.* 13, e005.
- Marchais-Oberwinkler, S., Henn, C., Möller, G., Klein, T., Negri, M., Oster, A., Spadaro, A., Werth, R., Wetzel, M., Xu, K., Frotscher, N., Hartmann, R.W., Adamski, J., 2011. 17beta-Hydroxysteroid dehydrogenases (17beta-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development. *J. Steroid Biochem. Mol. Biol.* 125, 66–82.
- Mareck, U., Geyer, H., Fussholzer, G., Schwenke, A., Haenelt, N., Piper, T., Thevis, M., Schanzer, W., 2010. Reporting and managing elevated testosterone/epitestosterone ratios—novel aspects after five years' experience. *Drug Test. Anal.* 2, 637–642.
- Martel, C., Rheau, E., Takahashi, M., Trudel, C., Couet, J., Luu-The, V., Simard, J., Labrie, F., 1992. Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues. *J. Steroid Biochem. Mol. Biol.* 41, 597–603.
- Marti, N., Galvan, J.A., Pandey, A.V., Trippel, M., Tapia, C., Muller, M., Perren, A., Fluck, C.E., 2017. Genes and proteins of the alternative steroid backdoor pathway for dihydrotestosterone synthesis are expressed in the human ovary and seem enhanced in the polycystic ovary syndrome. *Mol. Cell Endocrinol.* 441, 116–123.
- Matsumine, H., Hirato, K., Yanaihara, T., Tamada, T., Yoshida, M., 1986. Aromatization by skeletal muscle. *J. Clin. Endocrinol. Metab.* 63, 717–720.
- McConnell, J.D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H.L., Albertsen, P., Roehrborn, C.G., Nickel, J.C., Wang, D.Z., Taylor, A.M., Waldstreicher, J., 1998. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. *N. Engl. J. Med.* 338, 557–563.
- McNamara, K.M., Nakamura, Y., Miki, Y., Sasano, H., 2013. Phase two steroid metabolism and its roles in breast and prostate cancer patients. *Front. Endocrinol. (Lausanne)* 4, 116.
- McNamara, K.M., Sasano, H., 2015a. Beyond the C18 frontier: androgen and glucocorticoid metabolism in breast cancer tissues: the role of non-typical steroid hormones in breast cancer development and progression. *Steroids* 103, 115–122.
- McNamara, K.M., Sasano, H., 2015b. The intracrinology of breast cancer. *J. Steroid Biochem. Mol. Biol.* 145, 172–178.
- McNamara, K.M., Sasano, H., 2016. Androgen and breast cancer: an update. *Curr. Opin. Endocrinol. Diabetes Obes.* 23, 249–256.
- McTernan, P.G., Anwar, A., Eggo, M.C., Barnett, A.H., Stewart, P.M., Kumar, S., 2000.



- Gender differences in the regulation of P450 aromatase expression and activity in human adipose tissue. *Int. J. Obes. Relat. Metab. Disord.* 24, 875–881.
- Meloche, C.A., Falany, C.N., 2001. Expression and characterization of the human 3 beta-hydroxysteroid sulfotransferases (SULT2B1a and SULT2B1b). *J. Steroid Biochem. Mol. Biol.* 77, 261–269.
- Mendonca, B.B., Arnhold, I.J., Bloise, W., Andersson, S., Russell, D.W., Wilson, J.D., 1999. 17beta-hydroxysteroid dehydrogenase 3 deficiency in women. *J. Clin. Endocrinol. Metab.* 84, 802–804.
- Messenger, A.G., 1993. The control of hair growth: an overview. *J. Invest. Dermatol.* 101, 4S–9S.
- Miller, W.L., 2008. Androgen synthesis in adrenarche. *Rev. Endocr. Metabolic Disord.* 10, 3.
- Miller, W.L., Auchus, R.J., 2011. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. *Endocr. Rev.* 32, 81–151.
- Mitsiades, N., Sung, C.C., Schultz, N., Danila, D.C., He, B., Eedunuri, V.K., Fleisher, M., Sander, C., Sawyers, C.L., Scher, H.I., 2012. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. *Cancer Res.* 72, 6142–6152.
- Moeller, G., Adamski, J., 2009. Integrated view on 17beta-hydroxysteroid dehydrogenases. *Mol. Cell. Endocrinol.* 301, 7–19.
- Mohler, J.L., Titus, M.A., Bai, S., Kennerley, B.J., Lih, F.B., Tomer, K.B., Wilson, E.M., 2011. Activation of the androgen receptor by intratumoral bioconversion of androstenediol to dihydrotestosterone in prostate cancer. *Cancer Res.* 71, 1486–1496.
- Mostaghel, E.A., Biehl, H., Hernandez, S., Zhang, A., Bartlett, J., Corey, E., Penning, T.M., Oksala, R., True, L.D., Nelson, P., 2017. Contribution of mouse adrenal glands to intratumoral androgens and growth of castration-resistant prostate cancer xenografts. *J. Clin. Oncol.* 35, 224, 224.
- Mueller, J.W., Gilligan, L.C., Idkowiak, J., Arlt, W., Foster, P.A., 2015. The regulation of steroid action by sulfation and desulfation. *Endocr. Rev.* 36, 526–563.
- Muller, C., Pompon, D., Urban, P., Morfin, R., 2006. Inter-conversion of 17alpha- and 7beta-hydroxy-dehydroepiandrosterone by the human 11beta-hydroxysteroid dehydrogenase type 1. *J. Steroid Biochem. Mol. Biol.* 99, 215–222.
- Murai, T., Iwabuchi, H., Ikeda, T., 2005. Repeated glucuronidation at one hydroxyl group leads to structurally novel diglucuronides of steroid sex hormones. *Drug Metab. Pharmacokinet.* 20, 282–293.
- Murai, T., Samata, N., Iwabuchi, H., Ikeda, T., 2006. Human UDP-glucuronosyltransferase, UGT1A8, glucuronidates dihydrotestosterone to a monoglucuronide and further to a structurally novel diglucuronide. *Drug Metab. Dispos.* 34, 1102–1108.
- Nadeau, G., Bellemare, J., Audet-Walsh, E., Flageole, C., Huang, S.P., Bao, B.Y., Douville, P., Caron, P., Fradet, Y., Lacombe, L., Guillemette, C., Levesque, E., 2011. Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer. *J. Clin. Endocrinol. Metab.* 96, E1550–E1557.
- Nakamura, Y., Gang, H.X., Suzuki, T., Sasano, H., Rainey, W.E., 2009a. Adrenal changes associated with adrenarche. *Rev. Endocr. Metab. Disord.* 10, 19–26.
- Nakamura, Y., Hornsby, P.J., Casson, P., Morimoto, R., Satoh, F., Xing, Y., Kennedy, M.R., Sasano, H., Rainey, W.E., 2009b. Type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in the adrenal reticularis. *J. Clin. Endocrinol. Metab.* 94, 2192–2198.
- Nasiri, M., Nikolaou, N., Parajes, S., Krone, N.P., Valsamakis, G., Mastorakos, G., Hughes, B., Taylor, A., Bujalska, I.J., Gathercole, L.L., Tomlinson, J.W., 2015. 5alpha-Reductase type 2 regulates glucocorticoid action and metabolic phenotype in human hepatocytes. *Endocrinology* 156, 2863–2871.
- Nelson, V.L., Qin, K.N., Rosenfield, R.L., Wood, J.R., Penning, T.M., Legro, R.S., Strauss 3rd, J.F., McAllister, J.M., 2001. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. *J. Clin. Endocrinol. Metab.* 86, 5925–5933.
- Neunzig, J., Milhim, M., Schiffer, L., Khatri, Y., Zapp, J., Sanchez-Guijo, A., Hartmann, M.F., Wudy, S.A., Bernhardt, R., 2017. The steroid metabolite 16(beta)-OH-androstenedione generated by CYP21A2 serves as a substrate for CYP19A1. *J. Steroid Biochem. Mol. Biol.* 167, 182–191.
- Neunzig, J., Sanchez-Guijo, A., Mosa, A., Hartmann, M.F., Geyer, J., Wudy, S.A., Bernhardt, R., 2014. A steroidogenic pathway for sulfonated steroids: the metabolism of pregnenolone sulfate. *J. Steroid Biochem. Mol. Biol.* 144 Pt B, 324–333.
- Nikolakis, G., Stratakis, C.A., Kanaki, T., Slominski, A., Zouboulis, C.C., 2016. Skin steroidogenesis in health and disease. *Rev. Endocr. Metab. Disord.* 17, 247–258.
- Niwa, T., Murayama, N., Imagawa, Y., Yamazaki, H., 2015. Regioselective hydroxylation of steroid hormones by human cytochromes P450. *Drug Metab. Rev.* 47, 89–110.
- Noordam, C., Dhir, V., McNelis, J.C., Schlereth, F., Hanley, N.A., Krone, N., Smeitink, J.A., Smeets, R., Sweep, F.C., Claahsen-van der Grinten, H.L., Arlt, W., 2009. Inactivating PAPSS2 mutations in a patient with premature pubarche. *N. Engl. J. Med.* 360, 2310–2318.
- O'Reilly, M.W., House, P.J., Tomlinson, J.W., 2014a. Understanding androgen action in adipose tissue. *J. Steroid Biochem. Mol. Biol.* 143, 277–284.
- O'Reilly, M.W., Kempegowda, P., Jenkinson, C., Taylor, A.E., Quanson, J.L., Storbek, K.H., Arlt, W., 2016. 11-oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome. *J. Clin. Endocrinol. Metab.* jc20163285.
- O'Reilly, M.W., Taylor, A.E., Crabtree, N.J., Hughes, B.A., Capper, F., Crowley, R.K., Stewart, P.M., Tomlinson, J.W., Arlt, W., 2014b. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. *J. Clin. Endocrinol. Metab.* 99, 1027–1036.
- Ohmori, S., Fujiki, N., Nakasa, H., Nakamura, H., Ishii, I., Itahashi, K., Kitada, M., 1998. Steroid hydroxylation by human fetal CYP3A7 and human NADPH-cytochrome P450 reductase coexpressed in insect cells using baculovirus. *Res. Commun. Mol. Pathol. Pharmacol.* 100, 15–28.
- Okeigwe, I., Kuohung, W., 2014. 5-Alpha reductase deficiency: a 40-year retrospective review. *Curr. Opin. Endocrinol. Diabetes Obes.* 21, 483–487.
- Oostdijk, W., Idkowiak, J., Mueller, J.W., House, P.J., Taylor, A.E., O'Reilly, M.W., Hughes, B.A., de Vries, M.C., Kant, S.G., Santen, G.W., Verkerk, A.J., Uitterlinden, A.G., Wit, J.M., Losekoot, M., Arlt, W., 2015. PAPSS2 deficiency causes androgen excess via impaired DHEA sulfation—in vitro and in vivo studies in a family harboring two novel PAPSS2 mutations. *J. Clin. Endocrinol. Metab.* 100, E672–E680.
- Palermo, M., Marazzi, M.G., Hughes, B.A., Stewart, P.M., Clayton, P.T., Shackleton, C.H., 2008. Human Delta4-3-oxosteroid 5beta-reductase (AKR1D1) deficiency and steroid metabolism. *Steroids* 73, 417–423.
- Pasquali, R., Zanotti, L., Fanelli, F., Mezzullo, M., Fazzini, A., Morselli Labate, A.M., Repaci, A., Ribichini, D., Gambineri, A., 2016. Defining hyperandrogenism in women with polycystic ovary syndrome: a challenging perspective. *J. Clin. Endocrinol. Metab.* 101, 2013–2022.
- Patel, S.S., Beshay, V.E., Escobar, J.C., Carr, B.R., 2010. 17alpha-Hydroxylase (CYP17) expression and subsequent androstenedione production in the human ovary. *Reprod. Sci.* 17, 978–986.
- Payne, A.H., Clarke, T.R., Bain, P.A., 1995. The murine 3 beta-hydroxysteroid dehydrogenase multigene family: structure, function and tissue-specific expression. *J. Steroid Biochem. Mol. Biol.* 53, 111–118.
- Penning, T.M., 2010. New frontiers in androgen biosynthesis and metabolism. *Curr. Opin. Endocrinol. Diabetes Obes.* 17, 233–239.
- Penning, T.M., Burczynski, M.E., Jez, J.M., Hung, C.F., Lin, H.K., Ma, H., Moore, M., Palackal, N., Ratnam, K., 2000. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. *Biochem. J.* 351, 67–77.
- Penning, T.M., Jin, Y., Steckelbroeck, S., Lanisnik Rizner, T., Lewis, M., 2004. Structure-function of human 3 alpha-hydroxysteroid dehydrogenases: genes and proteins. *Mol. Cell Endocrinol.* 215, 63–72.
- Penning, T.M., Lee, S.-H., Jin, Y., Gutierrez, A., Blair, I.A., 2010. Liquid chromatography–mass spectrometry (LC–MS) of steroid hormone metabolites and its applications. *J. Steroid Biochem. Mol. Biol.* 121, 546–555.
- Piper, T., Riemann, P., Opfermann, G., Mareck, U., Geyer, H., Vajjala, G., Flenker, U., Schanzer, W., 2009. Determination of 13C/12C ratios of urinary epitestosterone and its main metabolites 5alpha- and 5beta-androstane-3alpha, 17alpha-diol. *Drug Test. Anal.* 1, 576–586.
- Piper, T., Schanzer, W., Thevis, M., 2016. Genotype-dependent metabolism of exogenous testosterone – new biomarkers result in prolonged detectability. *Drug Test. Anal.* 8, 1163–1173.
- Porola, P., Virkki, L., Przybyla, B.D., Laine, M., Patterson, T.A., Pihakari, A., Kontinen, Y.T., 2008. Androgen deficiency and defective intracrine processing of dehydroepiandrosterone in salivary glands in Sjogren's syndrome. *J. Rheumatol.* 35, 2229–2235.
- Povey, S., Lovering, R., Bruford, E., Wright, M., Lush, M., Wain, H., 2001. The HUGO gene nomenclature committee (HGNC). *Hum. Genet.* 109, 678–680.
- Pretorius, E., Africander, D.J., Vlok, M., Perkins, M.S., Quanson, J., Storbek, K.H., 2016. 11-Ketotestosterone and 11-ketodihydrotestosterone in castration resistant prostate cancer: potent androgens which can no longer be ignored. *PLoS One* 11, e0159867.
- Pretorius, E., Arlt, W., Storbek, K.H., 2017. A new dawn for androgens: novel lessons from 11-oxygenated C19 steroids. *Mol. Cell Endocrinol.* 441, 76–85.
- Pritchard, J.B., Miller, D.S., 1996. Renal secretion of organic anions and cations. *Kidney Int.* 49, 1649–1654.
- Puranen, T., Poutanen, M., Ghosh, D., Vihko, R., Vihko, P., 1997. Origin of substrate specificity of human and rat 17beta-hydroxysteroid dehydrogenase type 1, using chimeric enzymes and site-directed substitutions. *Endocrinology* 138, 3532–3539.
- Purohit, A., Foster, P.A., 2012. Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers. *J. Endocrinol.* 212, 99–110.
- Quinkler, M., Bumke-Vogt, C., Meyer, B., Bahr, V., Oelkers, W., Diederich, S., 2003. The human kidney is a progesterone-metabolizing and androgen-producing organ. *J. Clin. Endocrinol. Metab.* 88, 2803–2809.
- Quinkler, M., Sinha, B., Tomlinson, J.W., Bujalska, I.J., Stewart, P.M., Arlt, W., 2004. Androgen generation in adipose tissue in women with simple obesity—a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5. *J. Endocrinol.* 183, 331–342.
- Raine-Fenning, N.J., Brincat, M.P., Muscat-Baron, Y., 2003. Skin aging and menopause: implications for treatment. *Am. J. Clin. Dermatol.* 4, 371–378.
- Rainey, W.E., Nakamura, Y., 2008. Regulation of the adrenal androgen biosynthesis. *J. Steroid Biochem. Mol. Biol.* 108, 281–286.
- Reed, M.J., Purohit, A., Woo, L.W., Newman, S.P., Potter, B.V., 2005. Steroid sulfatase: molecular biology, regulation, and inhibition. *Endocr. Rev.* 26, 171–202.
- Rege, J., Nakamura, Y., Satoh, F., Morimoto, R., Kennedy, M.R., Layman, L.C., Honma, S., Sasano, H., Rainey, W.E., 2013. Liquid chromatography–tandem mass spectrometry analysis of human adrenal vein 19-carbon steroids before and after ACTH stimulation. *J. Clin. Endocrinol. Metab.* 98, 1182–1188.
- Remer, T., Boye, K.R., Hartmann, M.F., Wudy, S.A., 2005. Urinary markers of adrenarche: reference values in healthy subjects, aged 3–18 years. *J. Clin. Endocrinol. Metab.* 90, 2015–2021.

- Riches, Z., Stanley, E.L., Bloomer, J.C., Coughtrie, M.W., 2009. Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT "pie". *Drug Metab. Dispos.* 37, 2255–2261.
- Rittmaster, R.S., Zwicker, H., Thompson, D.L., Konok, G., Norman, R.W., 1993. Androstenediol glucuronide production in human liver, prostate, and skin. Evidence for the importance of the liver in 5 alpha-reduced androgen metabolism. *J. Clin. Endocrinol. Metab.* 76, 977–982.
- Rizner, T.L., Lin, H.K., Peehl, D.M., Steckelbroeck, S., Bauman, D.R., Penning, T.M., 2003. Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. *Endocrinology* 144, 2922–2932.
- Rodriguez, H., Hum, D.W., Staels, B., Miller, W.L., 1997. Transcription of the human genes for cytochrome P450sc and P450c17 is regulated differently in human adrenal NCI-H295 cells than in mouse adrenal Y1 cells. *J. Clin. Endocrinol. Metab.* 82, 365–371.
- Roy, R., Belanger, A., 1989. Lipoproteins: carriers of dehydroepiandrosterone fatty acid esters in human serum. *J. Steroid Biochem.* 34, 559–561.
- Ruokonen, A., 1978. Steroid metabolism in testis tissue: the metabolism of pregnenolone, pregnenolone sulfate, dehydroepiandrosterone and dehydroepiandrosterone sulfate in human and boar testes in vitro. *J. Steroid Biochem.* 9, 939–946.
- Russell, D.W., Wilson, J.D., 1994. Steroid 5 alpha-reductase: two genes/two enzymes. *Annu. Rev. Biochem.* 63, 25–61.
- Samson, M., Labrie, F., Zouboulis, C.C., Luu-The, V., 2010. Biosynthesis of dihydrotestosterone by a pathway that does not require testosterone as an intermediate in the SZ95 sebaceous gland cell line. *J. Invest. Dermatol.* 130, 602–604.
- Sanchez-Guijo, A., Neunzig, J., Gerber, A., Oji, V., Hartmann, M.F., Schuppe, H.C., Traupe, H., Bernhardt, R., Wudy, S.A., 2016. Role of steroid sulfatase in steroid homeostasis and characterization of the sulfated steroid pathway: evidence from steroid sulfatase deficiency. *Mol. Cell Endocrinol.* 437, 142–153.
- Sanchez-Guijo, A., Oji, V., Hartmann, M.F., Traupe, H., Wudy, S.A., 2015. Simultaneous quantification of cholesterol sulfate, androgen sulfates, and progestagen sulfates in human serum by LC-MS/MS. *J. Lipid Res.* 56, 1843–1851.
- Sato, K., Iemitsu, M., Matsutani, K., Kurihara, T., Hamaoka, T., Fujita, S., 2014a. Resistance training restores muscle sex steroid hormone steroidogenesis in older men. *FASEB J.* 28, 1891–1897.
- Sato, K., Samocha-Bonet, D., Handelsman, D.J., Fujita, S., Wittert, G.A., Heilbronn, L.K., 2014b. Serum sex steroids and steroidogenesis-related enzyme expression in skeletal muscle during experimental weight gain in men. *Diabetes Metab.* 40, 439–444.
- Satoh, T., Watanabe, K., Takanashi, K., Itoh, S., Takagi, H., Yoshizawa, I., 1992. Evidence of direct conversion of testosterone sulfate to estradiol 17-sulfate by human placental microsomes. *J. Pharmacobiodyn.* 15, 427–436.
- Sawaya, M.E., Price, V.H., 1997. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. *J. Invest. Dermatol.* 109, 296–300.
- Shackleton, C.H., Neres, M.S., Hughes, B.A., Stewart, P.M., Kater, C.E., 2008. 17-Hydroxylase/C17,20-lyase (CYP17) is not the enzyme responsible for side-chain cleavage of cortisol and its metabolites. *Steroids* 73, 652–656.
- Shackleton, C.H., Phillips, A., Chang, T., Li, Y., 1997a. Confirming testosterone administration by isotope ratio mass spectrometric analysis of urinary androstenediols. *Steroids* 62, 379–387.
- Shackleton, C.H., Roitman, E., Phillips, A., Chang, T., 1997b. Androstenediol and 5-androstenediol profiling for detecting exogenously administered dihydrotestosterone, epitestosterone, and dehydroepiandrosterone: potential use in gas chromatography isotope ratio mass spectrometry. *Steroids* 62, 665–673.
- Sharifi, N., 2012. The 5alpha-androstenedione pathway to dihydrotestosterone in castration-resistant prostate cancer. *J. Investig. Med.* 60, 504–507.
- Sharifi, N., Auchus, R.J., 2012. Steroid biosynthesis and prostate cancer. *Steroids* 77, 719–726.
- Sherbet, D.P., Tiosano, D., Kwist, K.M., Hochberg, Z., Auchus, R.J., 2003. CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding. *J. Biol. Chem.* 278, 48563–48569.
- Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., Guengerich, F.P., 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. *J. Pharmacol. Exp. Ther.* 270, 414–423.
- Shows, T.B., Alper, C.A., Bootsma, D., Dorf, M., Douglas, T., Huisman, T., Kit, S., Klinger, H.P., Kozak, C., Lalley, P.A., Lindsley, D., McAlpine, P.J., McDougall, J.K., Meera Khan, P., Meisler, M., Morton, N.E., Opitz, J.M., Partridge, C.W., Payne, R., Roderick, T.H., Rubinstein, P., Ruddle, F.H., Shaw, M., Spranger, J.W., Weiss, K., 1979. International system for human gene nomenclature (1979) ISGN (1979). *Cytogenet. Cell Genet.* 25, 96–116.
- Simard, J., Ricketts, M.L., Gingras, S., Soucy, P., Feltus, F.A., Melner, M.H., 2005. Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. *Endocr. Rev.* 26, 525–582.
- Simard, J., Sanchez, R., Durocher, F., Rheume, E., Turgeon, C., Labrie, Y., Luu-The, V., Mbarki, F., Morel, Y., de Launoit, Y., et al., 1995. Structure-function relationships and molecular genetics of the 3 beta-hydroxysteroid dehydrogenase gene family. *J. Steroid Biochem. Mol. Biol.* 55, 489–505.
- Simpson, E.R., 2003. Sources of estrogen and their importance. *J. Steroid Biochem. Mol. Biol.* 86, 225–230.
- Simpson, E.R., Clyne, C., Rubin, G., Boon, W.C., Robertson, K., Britt, K., Speed, C., Jones, M., 2002. Aromatase—a brief overview. *Annu. Rev. Physiol.* 64, 93–127.
- Slominski, A., Zbytek, B., Nikolakis, G., Manna, P.R., Skobowiat, C., Zmijewski, M., Li, W., Janjetovic, Z., Postlethwaite, A., Zouboulis, C.C., Tuckey, R.C., 2013. Steroidogenesis in the skin: implications for local immune functions. *J. Steroid Biochem. Mol. Biol.* 137, 107–123.
- Smith, R.E., Maguire, J.A., Stein-Oakley, A.N., Sasano, H., Takahashi, K., Fukushima, K., Krozowski, Z.S., 1996. Localization of 11 beta-hydroxysteroid dehydrogenase type II in human epithelial tissues. *J. Clin. Endocrinol. Metab.* 81, 3244–3248.
- Sobel, V., Zhu, Y.S., Imperato-McGinley, J., 2004. Fetal hormones and sexual differentiation. *Obstet. Gynecol. Clin. North Am.* 31, 837–856 x-xi.
- Spaan, M., Porola, P., Laine, M., Rozman, B., Azuma, M., Kontinen, Y.T., 2009. Healthy human salivary glands contain a DHEA-sulphate processing intracrine machinery, which is deranged in primary Sjogren's syndrome. *J. Cell Mol. Med.* 13, 1261–1270.
- Stanczyk, F.Z., Mathews, B.W., Sherman, M.E., 2015. Relationships of sex steroid hormone levels in benign and cancerous breast tissue and blood: a critical appraisal of current science. *Steroids* 99, 91–102.
- Steckelbroeck, S., Jin, Y., Gopishetty, S., Oyesanmi, B., Penning, T.M., 2004. Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. *J. Biol. Chem.* 279, 10784–10795.
- Stewart, P.M., Shackleton, C.H., Beastall, G.H., Edwards, C.R., 1990. 5 alpha-reductase activity in polycystic ovary syndrome. *Lancet* 335, 431–433.
- Storbeck, K.H., Bloem, L.M., Africander, D., Schloms, L., Swart, P., Swart, A.C., 2013. 11beta-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer? *Mol. Cell Endocrinol.* 377, 135–146.
- Sugawara, T., Holt, J.A., Driscoll, D., Strauss 3rd, J.F., Lin, D., Miller, W.L., Patterson, D., Clancy, K.P., Hart, I.M., Clark, B.J., et al., 1995. Human steroidogenic acute regulatory protein: functional activity in COS-1 cells, tissue-specific expression, and mapping of the structural gene to 8p11.2 and a pseudogene to chromosome 13. *Proc. Natl. Acad. Sci. U. S. A.* 92, 4778–4782.
- Sugimoto, Y., Lopez-Solache, I., Labrie, F., Luu-The, V., 1995. Cations inhibit specifically type I 5 alpha-reductase found in human skin. *J. Invest. Dermatol.* 104, 775–778.
- Suzuki, T., Miki, Y., Nakamura, Y., Moriya, T., Ito, K., Ohuchi, N., Sasano, H., 2005. Sex steroid-producing enzymes in human breast cancer. *Endocrine-Relat. Cancer* 12, 701–720.
- Swart, A.C., Schloms, L., Storbeck, K.H., Bloem, L.M., Toit, T., Quanson, J.L., Rainey, W.E., Swart, P., 2013. 11beta-hydroxyandrostenedione, the product of androstenedione metabolism in the adrenal, is metabolized in LNCaP cells by 5alpha-reductase yielding 11beta-hydroxy-5alpha-androstenedione. *J. Steroid Biochem. Mol. Biol.* 138, 132–142.
- Swart, A.C., Storbeck, K.H., 2015. 11beta-Hydroxyandrostenedione: downstream metabolism by 11betaHSD, 17betaHSD and SRD5A produces novel substrates in familiar pathways. *Mol. Cell Endocrinol.* 408, 114–123.
- Tchernof, A., Labrie, F., Belanger, A., Prud'homme, D., Bouchard, C., Tremblay, A., Nadeau, A., Despres, J.P., 1997. Androstane-3alpha,17beta-diol glucuronide as a steroid correlate of visceral obesity in men. *J. Clin. Endocrinol. Metab.* 82, 1528–1534.
- Tchernof, A., Levesque, E., Beaulieu, M., Couture, P., Despres, J.P., Hum, D.W., Belanger, A., 1999. Expression of the androgen metabolizing enzyme UGT2B15 in adipose tissue and relative expression measurement using a competitive RT-PCR method. *Clin. Endocrinol. (Oxf)* 50, 637–642.
- Tchernof, A., Mansour, M.F., Pelletier, M., Boulet, M.M., Nadeau, M., Luu-The, V., 2015. Updated survey of the steroid-converting enzymes in human adipose tissues. *J. Steroid Biochem. Mol. Biol.* 147, 56–69.
- Thigpen, A.E., Silver, R.I., Guileyardo, J.M., Casey, M.L., McConnell, J.D., Russell, D.W., 1993. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. *J. Clin. Invest.* 92, 903–910.
- Thomas, J.L., Buchholtz, K.M., Kacsob, B., 2011. Selective inhibition of human 3beta-hydroxysteroid dehydrogenase type 1 as a potential treatment for breast cancer. *J. Steroid Biochem. Mol. Biol.* 125, 57–65.
- Thomas, M.P., Potter, B.V., 2015. Estrogen O-sulfamates and their analogues: clinical steroid sulfatase inhibitors with broad potential. *J. Steroid Biochem. Mol. Biol.* 153, 160–169.
- Trabert, B., Xu, X., Falk, R.T., Guillemette, C., Stanczyk, F.Z., McGlynn, K.A., 2016. Assay reproducibility of serum androgen measurements using liquid chromatography–tandem mass spectrometry. *J. Steroid Biochem. Mol. Biol.* 155 (Part A), 56–62.
- Tremblay, Y., Belanger, A., Fleury, A., Beaudoin, C., Provost, P., Martineau, I., 1995. Studies of the Guinea pig adrenal cytochrome P450c17 cDNA. *Endocr. Res.* 21, 495–507.
- Turcu, A.F., Auchus, R.J., 2015. Adrenal steroidogenesis and congenital adrenal hyperplasia. *Endocrinol. Metab. Clin. North Am.* 44, 275–296.
- Turcu, A.F., Mallappa, A., Elman, M., Avila, N.A., Marko, J., Rao, H., Tsodikov, A., Auchus, R.J., Merke, D.P., 2017 Aug 1. 11-Oxygenated androgens are biomarkers of adrenal volume and testicular adrenal rest tumors in 21-hydroxylase deficiency. *J. Clin. Endocrinol. Metab.* 102 (8), 2701–2710.
- Turcu, A.F., Nanba, A.T., Chomic, R., Upadhyay, S.K., Giordano, T.J., Shields, J.J., Merke, D.P., Rainey, W.E., Auchus, R.J., 2016. Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency. *Eur. J. Endocrinol.* 174, 601–609.
- Uemura, M., Tamura, K., Chung, S., Honma, S., Okuyama, A., Nakamura, Y., Nakagawa, H., 2008. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. *Cancer Sci.* 99, 81–86.



- van Weerden, W.M., Bierings, H.G., van Steenbrugge, G.J., de Jong, F.H., Schroder, F.H., 1992. Adrenal glands of mouse and rat do not synthesize androgens. *Life Sci.* 50, 857–861.
- Vandenput, L., Mellstrom, D., Lorentzon, M., Swanson, C., Karlsson, M.K., Brandberg, J., Lonn, L., Orwoll, E., Smith, U., Labrie, F., Ljunggren, O., Tivesten, A., Ohlsson, C., 2007. Androgens and glucuronidated androgen metabolites are associated with metabolic risk factors in men. *J. Clin. Endocrinol. Metab.* 92, 4130–4137.
- VanWert, A.L., Gionfriddo, M.R., Sweet, D.H., 2010. Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. *Biopharm. Drug Dispos.* 31, 1–11.
- Vassiliadi, D.A., Barber, T.M., Hughes, B.A., McCarthy, M.I., Wass, J.A., Franks, S., Nightingale, P., Tomlinson, J.W., Arlt, W., Stewart, P.M., 2009. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. *J. Clin. Endocrinol. Metab.* 94, 3558–3566.
- Vermeulen, A., Verdonck, L., Kaufman, J.M., 1999. A critical evaluation of simple methods for the estimation of free testosterone in serum. *J. Clin. Endocrinol. Metab.* 84, 3666–3672.
- Vihma, V., Tikkanen, M.J., 2011. Fatty acid esters of steroids: synthesis and metabolism in lipoproteins and adipose tissue. *J. Steroid Biochem. Mol. Biol.* 124, 65–76.
- Vining, R.F., McGinley, R.A., Symons, R.G., 1983. Hormones in saliva: mode of entry and consequent implications for clinical interpretation. *Clin. Chem.* 29, 1752–1756.
- Voutilainen, R., Tapanainen, J., Chung, B.C., Matteson, K.J., Miller, W.L., 1986. Hormonal regulation of P450sc (20,22-desmolase) and P450c17 (17 alpha-hydroxylase/17,20-lyase) in cultured human granulosa cells. *J. Clin. Endocrinol. Metab.* 63, 202–207.
- Wada, W.A.-D.A., 2015. *Anti-doping Testing Figures Report*. [https://www.wada-ama.org/sites/default/files/resources/files/2015\\_wada\\_anti-doping\\_testing\\_figures\\_report\\_0.pdf](https://www.wada-ama.org/sites/default/files/resources/files/2015_wada_anti-doping_testing_figures_report_0.pdf).
- Wang, F., Koskela, A., Hämäläinen, E., Turpeinen, U., Savolainen-Peltonen, H., Mikkola, T.S., Vihma, V., Adlercreutz, H., Tikkanen, M.J., 2011. Quantitative determination of dehydroepiandrosterone fatty acyl esters in human female adipose tissue and serum using mass spectrometric methods. *J. Steroid Biochem. Mol. Biol.* 124, 93–98.
- Wang, F., Vihma, V., Badeau, M., Savolainen-Peltonen, H., Leidenius, M., Mikkola, T., Turpeinen, U., Hamalainen, E., Ikonen, E., Wahala, K., Fledelius, C., Jauhainen, M., Tikkanen, M.J., 2012. Fatty acyl esterification and deesterification of 17beta-estradiol in human breast subcutaneous adipose tissue. *J. Clin. Endocrinol. Metab.* 97, 3349–3356.
- Weinstein, R.L., Kelch, R.P., Jenner, M.R., Kaplan, S.L., Grumbach, M.M., 1974. Secretion of unconjugated androgens and estrogens by the normal and abnormal human testis before and after human chorionic gonadotropin. *J. Clin. Invest.* 53, 1–6.
- Wells, J.C.K., 2007. Sexual dimorphism of body composition. *Best Pract. Res. Clin. Endocrinol. Metabol.* 21, 415–430.
- Werner, R., Kulle, A., Sommerfeld, I., Riepe, F.G., Wudy, S., Hartmann, M.F., Merz, H., Dohnert, U., Bertelloni, S., Holterhus, P.M., Hiort, O., 2012. Testosterone synthesis in patients with 17beta-hydroxysteroid dehydrogenase 3 deficiency. *Sex. Dev.* 6, 161–168.
- Williams, R.T., 1959. *Detoxification Mechanisms: the Metabolism and Detoxification of Drugs, Toxic Substances and Other Organic Compounds*. Chapman and Hall.
- Wilson, E.M., French, F.S., 1976. Binding properties of androgen receptors. Evidence for identical receptors in rat testis, epididymis, and prostate. *J. Biol. Chem.* 251, 5620–5629.
- Wilson, H., Lipsett, M.B., 1966. Metabolism of epitestosterone in man. *J. Clin. Endocrinol. Metab.* 26, 902–914.
- Wilson, J.D., Griffin, J.E., Russell, D.W., 1993. Steroid 5 alpha-reductase 2 deficiency. *Endocr. Rev.* 14, 577–593.
- Wright, J.L., Kwon, E.M., Ostrander, E.A., Montgomery, R.B., Lin, D.W., Vessella, R., Stanford, J.L., Mostaghel, E.A., 2011. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. *Cancer Epidemiol. Biomarkers Prev.* 20, 619–627.
- Wu, C., Orozco, C., Boyer, J., Leglise, M., Goodale, J., Batalov, S., Hodge, C.L., Haase, J., Janes, J., Huss, J.W., Su, A.I., 2009. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. *Genome Biol.* 10, R130.
- Yamana, K., Labrie, F., Luu-The, V., 2010. Human type 3 5alpha-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride. *Horm. Mol. Biol. Clin. Invest.* 2, 293–299.
- Yang, M., Xie, W., Mostaghel, E., Nakabayashi, M., Werner, L., Sun, T., Pomerantz, M., Freedman, M., Ross, R., Regan, M., Sharifi, N., Figg, W.D., Balk, S., Brown, M., Taplin, M.E., Oh, W.K., Lee, G.S., Kantoff, P.W., 2011. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. *J. Clin. Oncol.* 29, 2565–2573.
- Zang, T., Tamae, D., Mesaros, C., Wang, Q., Huang, M., Blair, I.A., Penning, T.M., 2017. Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry. *J. Steroid Biochem. Mol. Biol.* 165 (Part B), 342–355.
- Zanger, U.M., Schwab, M., 2013. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacol. Ther.* 138, 103–141.